Jahresbericht Dermatologie USZ 2017/2018

Department of Dermatology

Biennial Report 2017/2018

Imprint Project lead: Prof. Lars French, MD Catherine Frey-Blanc Contact: c.frey-blanc@usz.ch Layout: www.klauserdesign.ch Print: N&E Print, Siebnen Circulation: 600 copies Copyright: Department of Dermatology, University Hospital Zurich

Contents

Editorial

4

1 Assignment

6

2

7

Mission statement

3 Team 4

Patient care and laboratories

8 10

5 Three departments in focus

a. Nursing

b. Laboratories: routine laboratories, dermatopathology & research laboratories

c. Allergy unit

13 13 14

6 Research

a. Three research groups in focus

b. Research groups

16 18 20

7

Clinical research: UHZ Department of Dermatology, clinical trials unit

32

8

Research collaborations – Skintegrity und university research priority project (URPP)

33

9

Research collaborations – foundations and associations: Bruno Bloch Foundation, Association for Research on Cancer of the Skin, Christine Kühne Center for Allergy Research and Education (CK-CARE)

35

10 Collaborations with other dermatology centers

a. Close collaborations including staff – rotations/exchanges with Kantonsspital Thurgau AG, Kantonsspital Winterthur, Kantonsspital Graubünden, Hochgebirgsklinik Davos and Zuger Kantonsspital

b. Partnership with other dermatology centers in Switzerland; Kantonsspital St. Gallen

15

37 37

38

11

Medical education and training

39

12

Congresses/scientific meetings: Zürcher Dermatologische Fortbildungstage (ZDFT) 2017/2018, Tagung Arbeitsgemeinschaft für Dermatologische Forschung (ADF) 2018 and others

43

13

Public relations

46

14

Museum of Wax Moulages

48

15

Promotions, grants, honors and awards

49

16

Partners, sponsors, collaboration with industry, fundraising

51

17

Publications in 2017 and 2018

52

Editorial Dear colleagues, friends, referring physicians, patients, partners and readers. On behalf of our team at the Department of Dermatology of the University Hospital Zurich, it is our pleasure to provide you with an update of our recent activities in this biennial report.

This biennial report covers 2017 and 2018. During these past two years, we continued to improve the quality of patient care, research and education in the fields of dermatology, venerology and allergology. In November 2018, our chairman, Prof. Dr. Lars E. French, left our department. He followed a call to become the chairman of the world- renowned Department of Dermatology and Allergology at the Ludwig-Maximilians- Universität in Munich. During his 12 years, he has built the Zurich Department to become world class, both in terms of patient care and research. With more than 100 original research papers per year, which in 2017 and then again in 2018 had an impact factor of more than 1,000, our research department ranks among the leading institutions in the world.

In the past two years, we also saw other faculty members following calls to lead Departments. Prof. Barbara Ballmer-Weber in 2018 became physician-in-chief ad personam in Allergology at the Cantonal Hospital in St. Gallen. In 2017 PD Dr. Dr. Wolfram Hötzenecker received the call to be physician-in-chief of the Dermatology and Allergology Department at the Kepler University Hospital in Linz. Last but not least, Prof. Dr. Dr. Alexander Navarini followed a call to become physician-in-chief and full professor for Dermatology at the Basel University Hospital. We have to thank all these colleagues for the many years they worked in Zurich and helped to build our Department.

Within our own Department, two members were promoted to associate professors ad personam. In January 2017, Prof. Thomas Kündig started as Professor for Immunodermatology, and in June 2017, Prof. Mitchell Levesque started as Professor for Experimental Dermatology. In June 2018, PD Dr. sc. nat. Pål Johansen was promoted to adjunct professor for Allergology and Immmunology. Also, in the past two years, six members received their Venia Legendi: PD Dr. sc. nat. Hans Dietmar Beer, PD Dr. sc. nat. Philipp Bosshard, PD Dr. nat. Emmanuel Contassot, PD Dr. med. Martin, Glatz, PD Dr. med. Simone Goldinger, PD Dr. med. Beda Mühleisen.

Cutaneous oncology is an important focus of our research. We have built a Skin Cancer Foundation for promoting both our melanoma research and expanding our extensive Biobank with live primary tumor cell lines that are linked to genomic, epigenomic and clinical data. Our thanks also go to the Bruno-Bloch Foundation, installed by the first chairman of our Department, which keeps supporting our research.

In terms of fund raising events, we remain active. After organizing a concert with Anne-Sophie Mutter in 2013 and with soprano Edita Gruberova and the Zurich Chamber Orchestra in 2015, the Bruno Bloch Foundation successfully organized a

4

performance of the renowned Béjart Ballet Lausanne at Theater 11 in Zurich in 2017.

Our department and the Bruno Bloch Foundation are extremely grateful to the above artists and the generous participants and donors for their continued generous support. Thanks to the efforts, especially of Prof. Lars French and Patrick Schaffter (www.brunoblochstiftung.ch), the foundation could double its yearly support to CHF 180,000 per year.

Prof. Lars E. French, MD Chairman Department of Dermatology University Hospital Zurich

Prof. Reinhard Dummer, MD Vice-Chairman Department of Dermatology University Hospital Zurich

Prof. Thomas Kündig, MD Senior Attending Physician, Head Outpatient Clinic, Research and Laboratories Department of Dermatology University Hospital Zurich

Year by year, we could also expand our already considerable third-party research funding, which reached approx. CHF 8 million in 2018. Our focus on cutaneous oncology is being promoted by a university-wide Research Priority Program in translational oncology. From 2012 to 2016, this program was financed with over CHF 6 million in collaboration with 11 outstanding physicians and scientists from the University of Zurich (www.cancer.uzh.ch). Based on an outstanding interim external evaluation, a further four years of funding with over CHF 11 million from 2017 to 2020 have been received. Secondly, several members of the Department of Dermatology in collaboration with clinician scientists in rheumatology, plastic surgery, angiology and pediatrics, as well as scientists and engineers from the University of Zurich and the Swiss Federal Institute of Technology in Zurich (ETHZ) under the direction of Prof. Dr. Sabine Werner (ETHZ) and Prof. L. French, won competitive seed-funding of CHF 1 million for a project called Skintegrity (www.hochschul-medizin.ch). The Skintegrity consortium in Zurich brings together leading experts in the above areas to address the need for more efficient diagnosis and therapy of major skin diseases and of acute and chronic wounds.

Our department also keeps expanding its clinical activities. The number of outpatient visits has grown to 75,000 in the year 2018 and to 1,600 inpatients per year.

In the past two years, twelve of our residents in training became successfully boardcertified in dermatology and venereology: Dr. Florian Anzengruber, Dr. Regula Brändli, Dr. Marie-Charlotte Brüggen, Dr. Samuel Conrad, Dr. Anna Frauchiger, Dr. Caroline Guillod, Dr. Omar Ali Hassan, Dr. Nicoletta Jaberg, Dr. Fabrice Kaufmann, Dr. Claudia Lang, Dr. Julia-Tatjana Maul, Dr. Selina Thurneysen. Also, eight residents in training became board certified in allergology and clinical immunology: Dr. Eugen Bersuch, Dr. Sabine Bruckert, Dr. Nadja Galliker, Dr. Caroline Guillod, Dr. Susann Hasler, Dr. Antonio Kolios and Dr. Iryna Yastremska.

Challenges lay ahead of us and we are preparing ourselves for these. In 2020, our more than one century old Department of Dermatology building will have to make room for a new construction, and all of our research will be moved to the campus at Schlieren. Our outpatient facilities will be relocated to the University Hospital Zurich Airport (UHZ Airport, see www.usz.ch/bau).

With this overview of selected milestones and developments for the period 2017 to 2018, we invite you in the name of our entire team to find out more on the following pages.

5

1

Assignment

The Department of Dermatology at University Hospital Zurich (UHZ) is devoted to the provision of sustained leadership in research, patient care and education in the fields of dermatology, venereology and allergology.

Our nationally and internationally recognized department includes centers of excellence for skin cancer, inflammatory and allergic skin diseases, and dermatologic surgery.

Our team of 47 specialist physicians offers high-level patient care in all areas of dermatology, venereology and allergology through our large-scale outpatient care clinic (Dermatologische Poliklinik), our inpatient dermatology service, our daycare unit and a network of tertiary care referral clinics covering a wide range of specialty areas, including melanoma and difficult pigmented lesions, non-melanoma skin cancers, cutaneous lymphoma, bullous and autoimmune skin disease, medical dermatology, psoriasis, hair and scalp disease, occupational and contact dermatitis, dermatologic surgery, dermatopathology and physical therapies (phototherapy, radiotherapy and laser therapy).

6

Our research activities focus on basic and translational research relevant to skin disease, primarily skin cancer and inflammatory skin diseases. The efforts of our research groups are reflected by regular publication in high-level journals and a high cumulative annual impact factor.

Collaboration and networking with talented scientists and research groups at the University of Zurich, ETH, collaborative networks such as the Cancer Network Zurich, and other leading European dermatology centers help to significantly strengthen our research activities.

Education is the third principle field of activity for our department. In the past few years, the department has focused its resources on pre- and post-graduate training, and the development and maintenance of DOIT (Dermatology Online with Interactive Technology), our innovative internet-based pre-graduate learning tool, in collaboration with the European Dermatology Forum.

2

Mission statement

Working in close collaboration with other departments and institutes at UHZ, the top priorities of the Department of Dermatology are to:

offer high-quality individual diagnosis and therapy for various skin diseases, and educate patients in skincare and the prevention of skin disease

provide a high level of teaching and training in dermatology at the preand post-graduate level

perform innovative basic and clinical research with the ultimate aim of helping to improve patient care

foster constructive collaboration and networks with private practitioners and primary and secondary institutional care providers

In fulfilling this mission, we aim to cement our position as one of the leading dermatology departments in Europe.

7

3

Team

Physicians

Nursing team

Administrative team

Lab team

Secretaries/assistants

8

Organization chart management

Management Head Nursing

Skin Cancer Prevention/ Quality Management

Vice-Chair Skin Cancer (Treatment)

Inpatient Clinic, Dermatosurgery

Clinical Manager

Outpatient Clinic/Research

Allergy Unit/ Teaching

Sandra Beeler-Trüssel

Prof. Ralph Braun, MD

Prof. Reinhard Dummer, MD

Prof. Dr. Jürg Hafner, MD

Alexander Kitzinger

Prof. Thomas Kündig, MD

Prof. Peter SchmidGrendelmeier, MD

Attending Physicians with extended responsibility Outpatient Clinic/ Cutaneous lymphoma

Dermatopathology

Dermatopathology

PD Emmanuella Guenova, MD, PhD

PD Jivko Kamarachev, MD

* Prof. Dmitry Kazakov, MD

Physical Treatments

Laurence Imhof, MD

Dermatosurgery

Dermatosurgery

External Relations

* PD Severin Läuchli, MD

* Stephan Nobbe, MD

* Catherine Frey-Blanc

Attending Physicians Outpatient Clinic

Dermatosurgery/ Day Care Unit

Florian Anzengruber, MD

Marjam Barysch-Bonderer, MD

Dermato-oncology/ Day Care Clinic

Johanna Mangana, MD

Dermatosurgery

Outpatient Clinic

Allergy Unit

Museum of Moulages

Allergy Unit

Inpatient Clinic

Dermatopathology/ Outpatient Clinic

* Sabine Bruckert, MD

* Carina Butzmann, MD

* Nadja Galliker, MD

* Michael Geiges, MD

* Julia Genser, MD

* Nora Gräni, MD

Isabel Kolm, MD

Outpatient Clinic

Pediatric Dermatology

Pediatric Dermatology

* Maya Wolfensperger,MD

* Martin Theiler, MD

PD Lisa Weibel, MD

Allergy Unit

Dermatopathology

* Sara Micaletto, MD

* PD Beda Mühleisen, MD

Inpatient Clinic/ Outpatient Immunosuppression Clinic Allergy Unit Clinic

* Carla Murer, MD

Mirjam Nägeli, MD

* Benno Schnyder, MD

* part time

9

4

Patient care and laboratories

In the Swiss healthcare system, the five university hospitals are responsible for providing virtually all of the country’s inpatient dermatology services. By contrast, outpatient care is available in both the private sector and public settings (university and cantonal hospitals). The UHZ Department of Dermatology is the largest academic dermatology center in Switzerland and provides stateof-the-art inpatient medical care for complex and rare skin problems. The department’s skilled surgeons perform complex surgical and histologically controlled procedures, and the team is able to administer complex chemotherapeutic regimens and intravenous immunotherapy, including antibodies and fusion molecules. We also provide an extensive range of outpatient services, including highly specialized consultations. Our department benefits from a large area referral base for these specialist activities and its own on-site histopathology laboratory.

Outpatient unit (polyclinic) and specialist care clinics Prof. Th. M. Kündig and his team of dermatologists and specialist nurses treat more than 22,000 patients on referral as part of more than 70,000 consultations a year.

In contrast to general outpatient clinics, patients benefit from the expertise of international specialists in the fields of dermatology and venereology, and more specifically in autoimmune disorders, psoriasis, atopic dermatitis, hidradenitis, acne and other severe dermatologic diseases, hair, hyperhidrosis, pediatric dermatology, urticaria and more. The site is home to a weekly interdisciplinary wound clinic, which is organized in collaboration with the departments of vascular surgery, angiology, orthopedics and plastic surgery, and is intended for patients with chronic difficult-to-heal wounds.

In our daycare unit, infusion therapies are administered in an outpatient setting. Most of our patients suffer from metastatic melanoma and are treated primarily using recently developed immunotherapies. These are highly effective treatment modalities. Further diseases treated at the daycare unit include inflammatory and autoimmune diseases, and cutaneous lymphoma. By relocating to a single room (C19), we have improved our monitoring capabilities, as it means one nurse and one physician can now be on site. The new, rapid point-ofcare laboratory analysis system for blood samples facili-

10

tates treatment of a shorter duration. Due to the rapidly increasing number of immunotherapies that are available, our capacity utilization has increased from 41% to 123%.

We offset the resulting shortage of space and personnel by optimizing various processes, and are continuing to work on other improvements with the aim of making each patient’s stay at our daycare unit as comfortable as possible.

Skin cancer center – part of the Comprehensive Cancer Center Zurich Our department’s certified (DKG: German Cancer Society) skin cancer center is headed by Prof. R. Dummer, who directs a team of expert skin cancer specialists (Prof. R. Braun, PD, Dr. E. Guenova and Dr. J. Mangana). The center comprises the following clinics: – The pigmented lesion & skin cancer prevention clinic: this clinic is headed by Prof. R. Braun and makes use of modern high-tech equipment (confocal microscopy, skin surface video-microscopy, dermatoscopy, fullbody imaging) for the early detection of melanoma.

– The skin cancer clinic is headed by Prof. R. Dummer and offers highly professionalized treatment and follow-up services for patients with different types of skin cancer (melanoma and non-melanoma skin cancer) as well as access to the most innovative clinical trials.

– The cutaneous lymphoma clinic is headed by PD Dr. Dr. E. Guenova and PD Dr. K. Kerl (until September 2018).

With the incidence of melanoma and other skin cancers growing worldwide and new therapies prolonging the survival of patients at advanced stages of the respective disease, complex medical care has become critical. The most effective care for complicated melanoma and skin cancer is provided in specialized referral centers such as the Skin Cancer Center, which is part of UHZ’s Cancer Center Zurich (www.cancercenter.ch). Our aims are to provide optimized melanoma therapy, record the best patient-reported treatment outcomes and carry out successful clinical and translational research, all of which require a dedicated interdisciplinary team.

In today’s rapidly evolving scientific environment, modern skin cancer management is a typical example of precision medicine. Networking and cooperative projects involving basic research at local, national and interna-

tional level are crucial here. The inclusion of well-established local basic research groups and cooperative projects – including the investigation of patient samples collected in the biobank – is especially sought after. Clinical research with clinical trials sponsored by pharmaceutical companies and initiated by investigators is essential for creating a critical understanding of clinical science.

Patients are regularly informed about these projects and actively support these efforts from time to time.

Dermatologic surgery and Mohs micrographic surgery Our dermatosurgery unit focuses on the surgical treatment of skin cancer through the application of Mohs micrographic surgery and “slow Mohs” following the “Tuebingen cake” technique. The staff team consists of Prof. J. Hafner, PD Dr. S. Läuchli, Dr. M. Barysch, Dr. S. Nobbe, Dr. S. Bruckert, Dr. M. Kunz, A. Reiser, A. Zambernardi, S. Kostadinova and other members. Together, they treat over 4,000 skin lesions (primarily malignant) each year. The vast majority can be operated on under tumescent local anesthesia. Frail and elderly persons are able to stay as inpatients for brief periods of hospitalization, making this center particularly suitable for geriatric dermatologic surgery. Specialized wound care is administered to a smaller number of patients, with a variety of debridement techniques and grafts being employed. Electrochemotherapy, CO2 laser surgery and other specialized techniques can also be provided.

Clinic for immunocompromised patients The clinic for immunocompromised patients is intended primarily for patients taking immunosuppressive medication following an organ or stem cell transplant, as well as patients taking continuous immunosuppressive medication to combat inflammatory diseases. The ultimate aim is to prevent skin cancer, as the risk of these patients developing non-melanoma skin cancer (NMSC) is at least 65 times higher than that of immunocompetent individuals.

In addition, we provide information on prevention by means of protective measures (clothing, sunscreen, etc.). The clinic benefits from extremely close cooperation with the UHZ Transplantation Center, whose coordinators regularly refer patients to the clinic. With patients who have undergone an organ transplant now living longer, the number of patients is on the increase. In 2018, more than 1,900 patients were seen as part of more than 3,000 consultations during the clinic’s specialized consultation hour.

We are also affiliated with international organizations such as SCOPE (Skin Care in Organ Transplant Patients Europe; scopenetwork.org) and ITSCC (International Transplant Skin Cancer Collaborative).

11

Physical treatment unit – including radiotherapy, phototherapy and laser therapy

Weekday inpatient ward

Headed by Dr. L. Imhof, this unit is equipped with the latest physical therapy technologies, including UVA1 devices, a full range of lasers, radiofrequency equipment and an intense pulsed light (IPL) platform.

Two modern X-ray devices for the superficial radiotherapy of skin cancer and selected refractory inflammatory diseases were recently installed. Over 3,000 treatments are performed each year.

The Department of Dermatology has a longstanding interest in the application of laser technology.

The laser therapy and aesthetic dermatology unit attracts patients from all over the world seeking treatment for aesthetic and skin conditions. We perform a full range of laser procedures, such as permanent hair removal, tattoo removal, laser treatment for vascular disorders, both fractional and traditional resurfacing, CO2 and erbium treatments, and skin tightening procedures. We also provide numerous other treatments, such as injections with botulinum toxin, soft tissue fillers and chemical peels.

Dr. L. Imhof, the director of the laser unit, pursues interdisciplinary collaboration with plastic surgeons, angiologists and gynecologists.

Headed by Dr. M. Nägeli, our weekday inpatient ward has a total of six beds for the provision of rapid, complex inpatient workups and short inpatient therapies. This unit also provides extracorporeal photopheresis (four photopheresis machines (as of January 2017) and another four beds) – a form of immunomodulatory treatment – to stem cell transplant recipients suffering from graft-versus-host disease, lung transplant recipients suffering from organ rejection, and cutaneous lymphoma (Sézary Syndrome) patients. The same floor is home to the bath therapy room, which is intended for the provision of complex dermatological therapies.

Our inpatient clinic The inpatient clinic provides 36 beds for the treatment of particularly severe and extensive forms of skin disease. It is especially suited to patients with refractory atopic dermatitis, psoriasis, complex autoimmune diseases, as well as skin cancer patients suffering from metastatic melanoma or cutaneous lymphoma and frail patients undergoing major skin cancer surgery for non-melanoma skin cancer. The medical staff (Prof. L. French, Prof. R. Dummer, Prof T. Kündig, Prof. J. Hafner, Dr. M. Nägeli, Dr. N. Galliker, Dr. N. Gräni and Dr. J.T. Maul, together with a team of staff physicians and residents) and the team of specialized nurses (S. Beeler, A. Andreoletti and more) apply their extensive knowledge and experience in order to provide the best possible care for severe skin diseases. The high level of therapeutic support, commitment and friendly atmosphere are highly valued by the patients.

Financial Key Facts

12

Number of leaves in inpatient clinic

2014 2015 2016 2017 2018 Change %

(2017–2018)

1,346 1,284 1,344 1,601 1,627 1.6%

Duration of stay of inpatients (average)

6.5

7.3

6.4

5.5

5.4

-1.8%

Case mix index

0.904

1.000

0.947

0.873

0.869

-0.5%

Number of outpatients

21,955

21,965

22,594

23,010

23,793

3.4%

Consultations outpatient setting

71,834

71,201

70,844

74,120

75,433

1.8%

Tax points (outpatient setting in thousand)

16,568

17,009

17,681

19,368

19,699

1.7%

Revenues

39,951

46,390

51,914

59,167

62,182

5.1%

Biopsies Dermatopathology

30,469

28,849

30,212

30,191

30,100

-0.3%

5

Three departments in focus

a. Nursing care The UHZ Nursing Practice Model provides a conceptual frame for nursing care at UHZ and articulates nursing’s contribution to quality care. At its core is the provision of relational, person-centered care to individuals and families. In 2018, the nursing services provided at the dermatological clinic focused extensively on working environments as well as patient and family-centered care. As part of these efforts, various joint occasions were organized on a cross-discipline basis as a means of strengthening the working environment through partnership-based cooperation and promoting cultural development at our clinic. Two central themes here were the type of care provided and the promotion of patients’ self-management strategies.

The aim of reference care is to establish a professional relationship with patients and their relatives. Caregivers are assigned to a patient and their family and

accompany them throughout their stay at the hospital.

They form an interface between the various disciplines and professions, and are informed about the process, enabling them to support patients with optimum effect.

Information sheets on various therapies and procedures have been prepared to provide support. This means that patients always have the opportunity to read information on their therapies when they need it. This creates a sense of security for the patients in an unfamiliar environment.

They are also encouraged to commit to self-management and learn how to deal with their illness.

Two brief training concepts – inhalation and anaphylaxis – for promoting the self-management of patients with allergies were developed based on evidence and integrated into the day-to-day work of the outpatient ward. All members of the inter-professional team were trained in correct inhalation techniques and the use of the autoinjector. This increased the professional competence and consulting quality of the nursing staff, promoted safe, correct inhalation and injection techniques, and boosted recognition of faulty applications and safe guidance toward patients. This makes it possible for the allergy ward’s inter-professional team to train patients in a structured, efficient and high-quality manner. According to initial experience, even people who have had an adrenaline autoinjector or inhaler for years greatly appreciate training of this kind and can benefit from it.

Sandra Beeler Head Nursing

Heiko Müller Clinical Nurse Specialist

UHZ Nursing Practice Model Publication: Naef, R., Petry, H., Staudacher, D., Spirig, R. (in press). “Das Praxismodell ist unser Kompass” – Das USZ-Praxismodell Pflege: Zentrale Elemente und erste Erfahrungen. Krankenpflege 13

b. Laboratories: routine laboratories, dermatopathology and research laboratories Routine laboratories The department manages fully equipped routine laboratories for dermatopathology, allergology, molecular diagnostics, mycology and serology/venereology. Together, they are accredited according to ISO 15189:2012. In the last 12 years, the number of orders has more than doubled overall (see graph).

Dermatopathology The dermatopathology team examines around 30,000 skin samples per year. We offer high-quality diagnostics on formalin-fixed and native tissues (such as frozen sections), which can be supplemented as required by specific immunopathological investigations (immunohistochemistry, immunofluorescence and innovative special stains).

Furthermore, we offer molecular biology examinations (PCR) for pathogens or lymphoma diagnostics. The UHZ Department of Dermatology has an internationally renowned biobank with a focus on skin tumors, which allows it to conduct additional molecular biology exams as required, and to combine the latest research with the dermatopathology findings. The establishment of the MelArray gene panel in particular has made it possible to offer personalized treatment to melanoma patients. Our close cooperation with colleagues from the Institute of Pathology enables us to discuss difficult cases from an interdisciplinary perspective on a weekly basis and to offer a wide range of additional molecular biological investigations. Our dermatopathology unit is a training center accredited by the international and European committees for dermatopathology (ICDP and UEMS). We attach great importance to the training of our future dermatologists and regularly hold dermatopathology courses for residents. Providing a personal and efficient service for our customers is extremely important to us, and we are always seeking to establish new partnerships and collaborations.

Other routine laboratories Aside from dermatopathology, the clinic is equipped with laboratories devoted to allergology, molecular diagnostics, mycology and syphilis serology. These labs are run by the laboratory head, PD Dr. P. Bosshard (together with Prof. P. Schmid-Grendelmeier in the allergology laboratory), and together analyze 15,000 patient samples per year. The allergology lab was among the first to use the ISAC (Immuno Solid-phase Allergen Chip) test in Switzerland, which allows for the simultaneous determination of

14

allergen-specific IgE against 112 allergenic components originating from more than 50 sources. The lymphocyte transformation test (LTT) and the basophil activation test (BAT) are both in routine use for diagnosing drug hypersensitivity and other allergic reactions.

Instances of syphilis have increased dramatically in the last 20 years (see figure). In the serology lab, several new cases are detected each week. Additionally, a multiplex PCR for genital ulcer disease has been developed that allows for the simultaneous detection of T. pallidum (syphilis), herpes type 1 and 2, and H. ducreyi (chancre).

Other tests in the molecular diagnostics lab include the T-cell receptor clonality (TcR) and the immunoglobulin heavy chain (IgH) assays for the diagnosis of lymphoproliferative disorders.

The mycology lab is renowned as a reference laboratory, in particular for dermatophyte infections. Thanks to the long-standing experience of the staff and the head of laboratory, this facility is able to provide courses and teaching sessions for various stakeholders, e.g. resident doctors, pharmacists and lab technicians.

Research laboratories The continued expansion of our research activities encompassing around 65 researchers has led to an expansion of our research space. We now operate research laboratories on the top floor of our department at Gloriastrasse 31, as well as in two research buildings at the new biomedical campus in Schlieren (Wagistrasse 12 and 14). The latter contain state-of-the-art equipment for performing competitive research in the fields of biochemistry, molecular biology, cell biology, immunology and allergy. For animal experiments, we have access to a modern animal house at UHZ and in Schlieren. Our research labs are certified according to ISO standards and comply with GMP guidelines for patient samples.

c. The allergy unit Diagnosis and management of the full range of allergic diseases

phylactic shock or severe cutaneous or systemic reactions such as DRESS, Stevens-Johnson syndrome and TEN). We provide a full range of skin tests, state-of-the-art in vitro diagnostics including cellular tests (BAT, modified LTT and cytotoxic assays) and, if necessary, a variety of provocation tests and drug deactivation protocols for vaccines, biopharmaceuticals, cytostatic drugs and so on.

Allergic diseases are increasingly common and account for around one third of our patients. We cover the full range of allergies, attending to allergy-related skin diseases such atopic dermatitis, urticaria and contact dermatitis. We also cover very common inhalant allergies such as rhinoconjunctivitis and allergic asthma due to pollen, mites or pets, as well as increasingly prevalent allergies and intolerances to food, e.g. nuts, celery and seafood and food components such as histamine, gluten and lactose. Hymenoptera-related allergies, (e.g. allergic reactions to bees or wasps) can be attended to and, if necessary, treated with highly efficient and fast-acting ultra-rush immunotherapy regimens. We offer the full range of diagnostic tools, including molecular-based allergy diagnosis, all kinds of provocation tests and a large variety of treatments with conventional drugs, biopharmaceuticals and immunotherapy. To fulfill the needs of our patients as effectively as possible, we maintain very close interdisciplinary ties with Clinical Immunology, ENT, Gastroenterology, Hematology, Pulmonology and departments providing innovative immunotherapies.

Patient education is one of our priorities. We adopt an interprofessional approach in order to provide and teach individual patient education for anaphylaxis, asthma and atopic dermatitis. In addition, we maintain ties with special clinics that cover rarer diseases such as mastocytosis and hereditary angioedema.

Drug hypersensitivity – a major challenge

As there is an increasing need for well-trained personnel, we offer training opportunities to young doctors to become board-certified specialists in allergies and immunology and training opportunities for allied health professionals.

Hypersensitivity to drugs is common and ranges from harmless rashes to life-threatening conditions (ana-

Education of patients and health professionals

For mastocytosis, an interdisciplinary board together with hematology, rheumatology, gastroenterology and psychosomatic experts has been initiated by Dr. Claudia Lang. It allows us to treat our mastocytosis patients in accordance with the latest international guidelines and treatment protocols.

15

6

Research

One ongoing aim is to improve the quality of our services for patients. We are committed to the highest level of research in dermatology. Our achievements in this field – as judged by the cumulative impact factors for 2017 and 2018 (1156 and 1089) – position us among the world’s leading departments.

Our research activities focus primarily on basic, patient-oriented translational and clinical research in dermato-oncology, where we concentrate on the pathogenesis, early diagnosis and targeted treatment of skin cancer, particularly of melanoma, cutaneous lymphoma and non-melanoma skin cancers. Immunodermatology is also a research focus, in particular innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions and severe allergic adverse drug reactions. Allergy research is centered on atopic dermatitis, drug and food allergy as well as immunotherapy.

The aim of our research activities is to: – promote high-quality research with clinical relevance in the defined fields of focus.

– promote intensive networking and collaboration with other institutes and departments at the University of Zurich and ETH, and through active participation in networks such as Cancer Network Zurich and Life Science Zurich.

– support fellowships abroad in excellent research institutions and maximize competitive research funding, including from the Swiss National Science Foundation (SNF professorships).

– create endowed professorships in our department for inflammatory skin disease, skin cancer and allergy, with the aim of recruiting and retaining leaders in these research fields.

Impact Factor (Publications), 2004–2018

Year

16

Key figures and highlights

SSS Weekend (Science, Sun and Snow)

Approximately 40 clinical trials on new therapeutic approaches for skin disease are ongoing, corresponding to around 15% of all studies performed at UHZ. In 2018, our department published more than 140 original research articles and approximately 44 reviews in peer-reviewed journals.

Our 22nd and 23rd Science, Sun and Snow (SSS) weekends took place in 2017 and 2018. Approximately 50 researchers participated in this event, which was held in the Ameron Hotel and Arabella Hotel in Davos. Over the course of one and a half days, our young researchers presented their work and updated the attendees on their progress, which also led to intense discussions. The event also included a ski day, dinner and a fondue evening, creating the perfect atmosphere for scientific exchange.

A number of original publications have appeared in high-impact interdisciplinary journals, including: Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2018;19(5):603-615 Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MM, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res. 2019;7(1):77-85 Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018;24(2):144-153

“We are proud to be at the forefront of clinical and basic research in dermatology.”

Prof. Thomas Kündig, MD Head Research Department of Dermatology University Hospital Zurich

Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, Kiefer B, Ospelt C, Nobbe S, Thome M, Contassot E, French LE. CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J Invest Dermatol.

2018;138(9):2010-2023 Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Cell. 2018:9;174(4):1031-1032 17

a. Three research groups in focus In this report, we would like to look at three of our 14 research groups in more detail as a means of demonstrating the scope of research in our department.

1. “Tools for precision medicine in melanoma” Prof. Mitchell Levesque, PhD Recently, melanoma therapies have experienced dramatic success in the clinic, with more than half of all patients receiving some benefit. With access to one of the largest live-cell melanoma biobanks in the world, we have a unique resource through which to study the mechanisms of how gene expression and cellular diversity contribute to the ability of melanoma tumors to respond to targetedor immunotherapies. For instance, we – together with other groups – have contributed to the development of a “phenotype switching” model of melanoma progression, in which cancer cells are able to alternate between different fates and cellular behaviors (Figure 1).

Figure 1: Phenotype switching model of melanoma development. De novo events induce oncogenic and tumor suppressor mutations that convert a benign melano-

18

cyte into a melanoma cell. Most of these initial melanoma cells are melanocytic in nature (green), but a phenotype switch as the result of micro-environmental stresses (such as hypoxia, tumor lymphocyte infiltration, etc.) or therapeutic intervention can induce mesenchymal features (red). The role of that switch in tumor progression and therapeutic resistance is the main focus of our research.

Some projects in our lab are aiming to acquire a better understanding of how this switching behavior occurs in tumors in different contexts (e.g. by using single-cell sequencing approaches or proteomics techniques such as CyTOF). Meanwhile, other projects aim to target the novel features of cells that switch between these fates. By screening thousands of small compounds, we may be able to identify drugs that can specifically kill cells in each of these melanoma fates. We hope some of these novel drugs could one day lead to better tumor control in the clinic.

2. “Tracing a dream with light-sensitive substances” PD Pal Johansen, PhD, and Prof. Thomas Kündig, MD

3. “A Focus on RNA” PD Steve Pascolo, PhD

A vaccination that protects against cancer is a longstanding dream in medicine. This dream has now become a reality thanks to the vaccination against human papillomavirus infections and therefore protection against the cervical cancer that they can trigger. However, serious success has thus far eluded us when it comes to protection against other types of cancer. This is because the immune system can process vaccines in two ways and cancer vaccines are processed in the wrong way.

Gene information encoded by DNA is transcribed into messenger RNA (mRNA) that are translated into protein.

The mRNA can be synthesized in vitro (“ivt mRNA”) and transfected in cells in order to express the desired protein.

Because ivt mRNAs are transiently present in the cytosol, their use is safe and highly effective.

Every immune response begins with specialized antigen-presenting cells (APCs) absorbing the antigen. Depending on whether the antigen floats inside the defense cells in an endosome or freely in the cytosol, it is degraded in different ways and identified on the surface of the APC. By default, antigens enter the endosome and from there ultimately reach the MHC2 complex, which plays a key role in the immune system, especially in the interactions for the production of antibodies. However, when an antigen enters the cytosol, it binds to the MHC1 complex, which is primarily associated with the maturation of cytotoxic T-cells (CTLs).

CTLs are more effective than antibodies in the fight against tumor cells. The aim of our research project is therefore to transfer the vaccines from the endosomes into the cytosol of the APCs. In experiments with mice, we injected the vaccine together with a light-sensitive substance under the skin. When the mice were irradiated with intense light, the light-sensitive substance caused the endosomes inside the APCs to burst. This resulted in the vaccine entering the cytosol, and the immune response led to an increased formation of cancer cell-killing CTLs.

The mRNA platform at URPP – Translational Cancer Research – provides optimized (“AptaMessengerTM”; Figure below) and purified ivt mRNAs as well as optimized formulations for the desired site/duration of expression.

Through this, fundamental and pre-clinical investigations aiming at studying or utilizing a protein activity in vitro or in vivo can be undertaken in all research groups of the dermatology department as well as at collaborating institutions in Switzerland.

This photochemical internalization (PCI) works well in vitro and in mice. In cooperation with an industrial partner, the first experiments on humans are now underway. If the results from animal experiments are confirmed, we will have taken medicine another step closer toward fulfilling our dream.

Figure: AptaMessenger TM

19

b. Research groups

Prof. Barbara Ballmer-Weber, MD Group Members and Associates Prof. Barbara Ballmer-Weber, MD (group leader) Caroline Guillod, MD Claudia Lang, MD Nora Gräni, MD Muriel Trächsler

Main Fields of Research Our research activities are focused on food allergy, in particular pollen-related food allergy. We are especially involved in the identification and molecular characterization of important cross-reactive allergens, and the development of diagnostic and therapeutic methods based on recombinant allergens. Allergen-based or component resolved diagnosis in food allergy is a major topic of our research group. Another important aspect of our research activity is risk assessment in food allergy with regard to genetic modified foods/novel foods but also threshold doses (minimal allergen doses to induce an allergic reaction) of plant and animal food allergens.

Selected References Datema MR, van Ree R, Asero R, Barreales L, Belohlavkova S, de Blay F, Clausen M, Dubakiene R, Fernández-Perez C, Fritsche P, Gislason D, Hoffmann-Sommergruber K, Jedrzejczak-Czechowicz M, Jongejan L, Knulst AC, Kowalski M, Kralimarkova TZ, Le TM, Lidholm J, Papadopoulos NG, Popov TA, Del Prado N, Purohit A, Reig I, Seneviratne SL, Sinaniotis A, Versteeg SA, Vieths S, Zwinderman AH, Mills ENC, Fernández-Rivas M, Ballmer-Weber B. Component resolved diagnosis and beyond: multivariable regression models to predict severity of hazelnut allergy. Allergy 2018;73:549–559.

Ballmer-Weber BK, Beyer K. Food challenges. J Allergy Clin Immunol. 2018;141:69-71.

20

PD Hans-Dietmar Beer, PhD Group Members and Associates PD Hans-Dietmar Beer, PhD Serena Grossi (Postdoc), PhD Gabriele Fenini (Postdoc), PhD Martha Garstkiewicz (Postdoc, until 10/2018), PhD Paulina Hennig (PhD student) Michela di Filippo (PhD student)

Main Fields of Research The group is interested in the molecular mechanisms underlying inflammation and cancer development in human skin. The focus is on the roles of inflammasomes expressed by epidermal keratinocytes in these processes. Studies are based on patient-derived primary cells, such as keratinocytes, skin cancer cells and (cancer-associated) fibroblasts. The dermal-epidermal crosstalk of wildtype cells and those modified by the CRISPR/Cas9 approach is analyzed in a three-dimensional skin model. State-of-the-art proteomics approaches are used to identify novel regulatory pathways.

Selected References Hennig P, Garstkiewicz M, Grossi S, Di Filippo M, French LE, Beer HD. The Crosstalk between Nrf2 and Inflammasomes.

Int J Mol Sci 2018; 19(29).pi: E562 Sand J, Haertel E, Biedermann T, Contassot E, Reichmann E, French LE, Werner S, Beer HD. Expression of inflammasome proteins and inflammasome activation occurs in human, but not in murine keratinocytes. Cell Death & Disease 2018; 9:24, Grossi S, Fenini G, Garstkiewicz M, Biedermann T, Reichmann E, French L, Beer HD. Genome editing of human primary keratinocytes

by CRISPR/Cas9 reveals an essential role of NLRP1 in UVB sensing. Journal of Investigative Dermatology 2018; 138: 2644-2652

21

PD Philipp P. Bosshard, PhD PD Martin Glatz, MD Group Members and Associates Cheryl Leong Kit Mun, PhD Bettina Schmid, PhD student Ksenia Mischler, MD student Riccardo Curatolo, MD student Nada Juricevic, technician

Main Fields of Research Our research activities focus on skin infections and pathogen-host interactions. This comprises research on bacterial infections (e.g. sexually transmitted infections), fungal infections and the role of the human skin microbiome in inflammatory skin diseases such as atopic dermatitis. Our main interests are epidemiological studies, to develop and improve diagnostic tools for skin infections (e.g. PCR) and to research the human skin microbiome (e.g. next generation sequencing).

Selected References Grillová L, Bawa T, Mikalová L, Gayet-Ageron A, Nieselt K, Strouhal M, Sednaoui P, Ferry T, Cavassini M, Lautenschlager S, Dutly F, Pla-Díaz M, Krützen M, González-Candelas F, Bagheri HC, Šmajs D, Arora N, Bosshard PP. Molecular characterization of Treponema pallidum subsp. pallidum in Switzerland and France with a new multilocus sequence typing scheme. PLoS One. 2018;13(7):e0200773.

Glatz M, Jo JH, Kennedy EA, Polley EC, Segre JA, Simpson EL, Kong HH. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS One. 2018: 13(2):e0192443.

Glatz M, Bosshard P, Schmid-Grendelmeier P. The Role of Fungi in Atopic Dermatitis. Immunol Allergy Clin North Am 2017;37:63–74.

Leong C, Buttafuoco A, Glatz M, Bosshard PP. Antifungal susceptibility testing of Malassezia spp. with an optimized colorimetric broth microdilution method. J Clin Microbiol. 2017;55(6):1883-1893.

Glatz M, Means T, Haas J, Steere AC, Müllegger RR. Characterization of the early local immune response to Ixodes ricinus tick bites in human skin. Exp Dermatol 2017;26(3):263-269.

22

Prof. Ralph Braun, MD Group Members and Associates Florentia Dimitriou, MD Michael Kunz, MD Thierry Nordmann, MD

Main Fields of Research Our main interest is non-invasive diagnosis of skin cancer, especially malignant melanoma. We use established techniques such as dermoscopy as well as new techniques in vivo laser scanning microscopy. We also have a strong interest in artificial intelligence.

Due to different international research collaborations, our patients benefit directly from the latest technological developments. Detecting skin cancer, especially melanoma, at early stages offers a unique opportunity because, if diagnosed early enough, skin cancer can be cured.

Selected References www.dermoscopedia.org Braun RP, Ulrich K, Hunger R, Gaide O, Arnold A, Merat R, Dummer R, Hafner J, French LE, Cozzio A. Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right Thing. Dermatology. 2017;233(5):404-409 Yélamos O, Braun RP, Liopyris K, Wolner ZJ, Kerl K, Gerami P, Marghoob AA. Usefulness of dermoscopy/dermatoscopy to improve the clinical and histopathologic diagnosis of skin cancers. J Am Acad Dermatol. 2018 Oct 12. pii: S0190-9622(18)32728-2 [Epub ahead of print] Yélamos O, Braun RP, Liopyris K, Wolner ZJ, Kerl K, Gerami P, Marghoob AA. Dermoscopy/dermatoscopy and dermatopathology correlates of cutaneous neoplasms. J Am Acad Dermatol. 2018 Oct 12. pii: S0190-9622(18)32729-4. doi: 10.1016/j.jaad.2018.07.073. [Epub ahead of print]

23

Prof. Reinhard Dummer, MD Group Members and Associates Prof. Mirjana Maiwald, MD Prof. Mitchell Levesque, PhD Joanna Mangana, MD PD Simone Goldinger, MD Phil Cheng, Ph.D; Daniel Hug; Egle Ramelyte; Sabine Ludwig; Natalie Graf; Corinne Eggenschwiler; Corina Kaufmann; Johanna Ziegler; Peter Kölblinger; Marie-Luise Hilbers, Marieke Raaijmakers, MD

Main Fields of Research The team has established a world-class skin cancer center providing the best clinical care connected to translational and clinical research. We intensively investigate the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with the best quality of life.

Selected References Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-615 Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813-1823 Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109-1119

24

Prof. Lars E. French, MD Group Members and Associates Emmanuel Contassot, PhD/PD Takashi Satoh, MD/PhD Mark Mellett, PhD Barbara Meier-Schiesser, MD/PhD Gabriele Fenini, PhD Marie-Charlotte Brüggen, MD/PhD Nick Li, research associate Annika Klug, research associate

Main Fields of Research Cutaneous inflammation is a very common condition in dermatology, and numerous insults from the environment or endogenous danger signals can lead to inflammation. The aim of our research is to better understand the molecular events leading to inflammatory responses in the skin. We are particularly interested in the mechanisms involved in i) the immune responses involved in cutaneous adverse drug reactions such as Acute Generalized Exanthematous Pustulosis; ii) the regulation of keratinocyte inflammasomes in response to danger signals; iii) the role of CARD14 variants in psoriasis. We found that i) the inflammatory cytokine IL-36 is overexpressed in AGEP patients’ myeloid cells and keratinocytes in response to drug exposure; ii) the p38 MAP-kinase positively regulates the NLRP1 inflammasome in primary keratinocytes; and iii) the presence of gain-of-function mutations in CARD14 is sufficient to induce a psoriasiform phenotype in mice. These new findings highlight the key role of deregulated innate immunity in the skin and keratinocytes in pathological conditions.

Selected References Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, Navarini A, Abe R, Yawalkar N, Chung WH, French LE, Contassot E. Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis.J Invest Dermatol.

2018;139(4):848–858 Fenini G, Grossi S, Gehrke S, Beer HD, Satoh TK, Contassot E, French LE. The p38 Mitogen-Activated Protein Kinase Critically Regulates Human Keratinocyte Inflammasome Activation. J Invest Dermatol. 2018;138(6):1380-1390.

Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, Kiefer B, Ospelt C, Nobbe S, Thome M, Contassot E, French LE. CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J Invest Dermatol.

2018;138(9):2010-2023.

25

PD Emmanuella Guenova, MD, PhD Group Members and Associates Christina Fassnacht, PhD Eleni Varypataki, PhD Malgorzata Bobrowicz PhD Desislava Ignatova, PhD student Yung-Tsan Chang, PhD student Ieva Saulite, MD student Tanja Schläpfer, MD student Elina Stoffel, MD student Christoph Iselin, MSc student Anja Moczsko, MSc student Ilka Edendorf, MTA diagnostic Agathe Duda, MTA diagnostic

Main Fields of Research Our research activities focus on; i) Interactions between innate and adaptive immunity in cutaneous inflammation; ii) pathogenesis and therapy of skin tumors, particularly cutaneous lymphoma; iii) development of new immune therapies and translational research.

Selected References Anzengruber F*, Ignatova D*, Schlaepfer T, Chang YT, French LE, Pascolo S, Contassot E, Bobrowicz M, Hoetzenecker W, Guenova E. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome. Leuk Lymphoma. 2019 [Epub ahead of print] Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E*, Schoppmann SF*. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology. 2018; 13;7(6):e1435226 * Mangold AR, Thompson A, Davis MD, Saulite I, Cozzio A, Guenova E, Hodak E, Amitay-Laish I, Pujol RM, Pittelkow MR, Gniadecki R. Early clinical manifestations of Sézary syndrome: A Multicenter Retrospective Cohort Study. J Am Acad Dermatol 2017;77(4):719-727.

26

Prof. Jürg Hafner, MD Division of In-Hospital Dermatology and Surgical Dermatology Group Members and Associates In-Hospital Dermatology: Mirjam Nägeli, MD; Nora Gräni, MD; Tatjana Maul, MD Surgical Dermatology: Marjam Barysch, MD; PD Severin Läuchli, MD; Sabine Bruckert, MD; Stephan Nobbe, MD; Michael Kunz, MD Vascular Medicine, Wound Healing: Caroline Buset, med. pract.; Michael Kockaert, MD; PD Benedikt Weber, MD, PhD; Julia Deinsberger, MD

Main Fields of Research Dermatology in severely ill patients Dermatologic surgery and surgical oncology, local anesthesia Dermatology in immunosuppression Dermatologic angiology and phlebology Wound healing, compression therapy Principle Investigator of SKINTEGRITY

Selected References Lanz J et al.: Aggressive squamous cell carcinoma in organ transplant recipients. JAMA Dermatol. 2019;155(1):66-71.

Pich C. et al. Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth Cancer Res. 2018;78(22):6447-6461 Zimmerli D et al. WNT ligands control initiation and progression of human papilloma-virus-driven squamous cell carcinoma.

Oncogene 2018;37(27):3753-3762 Kolios AGA et al. Comparison of pyoderma gangrenosum and hypertensive ischemic leg ulcer Martorell in a Swiss cohort.

Br J Dermatol. 2018;178(2):e125-126.

Rabe E et al. Indications for medical compression stockings in venous and lymphatic disorders: An evidence-based consensus statement. Phlebology. 2017;33(3):163-184

27

Prof. Thomas Kündig, MD Antonia Gabriel-Fettelschoss, PhD Prof. Pål Johansen, PhD, Deborah Leuthard, MD Group Members and Associates Prof. Martin Bachmann, PhD; Prof. Gabriela Senti, MD; Prof. Pål Johansen, PhD; PD Steve Pascolo, PhD; PD Ying Waeckerle-Men, PhD; Gary Jennings, PhD; Antonia Gabriel-Fettelschoss. PhD; Victoria Fettelschoss; Franziska Thoms Zabel, PhD; Eleni Varypataki, PhD; Sarah Kindgen, PhD; Ásdís Hjálmsdóttir, PhD; Deborah Leuthard, MD; Isabella Domman, Master; Stefanie Haas, Master; Florian Olomski, Master; Anna Wiegand, Master; Corinne Zurfluh, Master

Main Fields of Research Our research group is focused on immunotherapy of allergies and cancer. In the area of allergies, we aim to improve and shorten current regimens for immunotherapy or desensitization, which today require three to five years of allergen administration. We found that direct administration of allergens into a lymph node made it possible to shorten immunotherapy from 60 to merely three injections. Also, we developed epicutaneous immunotherapy, where allergens are applied by use of a skin patch, shortening a course of treatment to merely six patch applications. Using virus-like particles, we aim to further reduce the number of allergen applications to one or two.

We are also using virus-like particles for anti-cytokine vaccination in horses and dogs as well as in cats to render them hypoallergenic. In the area of cancer research, we focus on the role of cytokines in tumor cachexia and we are working on RNA-based cancer vaccines.

Selected References Treating insect-bite hypersensitivity in horses with active vaccination against IL-5.

Fettelschoss-Gabriel A, Fettelschoss V, Thoms F, Giese C, Daniel M, Olomski F, Kamarachev J, Birkmann K, Bühler M, Kummer M, Zeltins A, Marti E, Kündig TM, Bachmann MF. J Allergy Clin Immunol. 2018;142(4):1194-1205 Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.

Leuthard DS, Duda A, Freiberger SN, Weiss S, Dommann I, Fenini G, Contassot E, Kramer MF, Skinner MA, Kündig TM, Heath MD, Johansen P. J Immunol. 2018;200(9):3151-3159 Intralymphatic Immunotherapy: Update and Unmet Needs.

Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, Di Bona D, Pfaar O, Ahlbeck L, Akdis M, Weinfeld D, Contreras-Verduzco FA, Pedroza-Melendez A, Skaarup SH, Lee SM, Cardell LO, Schmid JM, Westin U, Dollner R, Kündig TM. Int Arch Allergy Immunol. 2018; 1-9

28

Prof. Alexander Navarini, MD, PhD Group Members and Associates Rebecca Higgins, PhD Adhideb Ghosh, PhD Florian Anzengruber, MD univ.

Mathias Drach, MD univ.

Liliane Kaufmann, Stud MD Moritz Klinger, Stud MD Katja Hofstetter, Stud MD Associated members (from Inflammatory Dermatoses Study Team and Patch Test Unit) Tamsyn Meyer Julia Püschel Jasmine Narainsing

Main Fields of Research The focus of our activities is the investigation of inflammatory skin disease, especially neutrophil-mediated inflammatory dermatoses (NMID). We have two groups of investigators working on projects addressing genetic & pathophysiological questions (NMID-Team), as well as a newer and smaller Vision-Team, whose aim is to transform visual information into quantifiable phenotypic data.

Selected References Anzengruber F, Alotaibi F, Kaufmann LS, Ghosh A, Oswald MR, Maul JT, Meier B, French LE, Bonmarin M, Navarini AA. Thermography: High sensitivity and specificity diagnosing contact dermatitis in patch testing. Allergol Int. 2018;68(2):254–258 Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–708

29

PD Steve Pascolo, PhD Group Members and Associates Marina Tusup, PhD, scientist

Main Fields of Research The main focus of our research is the therapeutic utilization of RNA. We develop multifunctional anti-cancer immunochenotherapeutic RNA formulations. Within the University Research Priority Program (URPP) “Translational Cancer Research”, we generate and formulate mRNA for expression of therapeutic proteins. As we have done in the past, those RNA-based strategies can be tested in clinical trials. In addition, we study epitranscriptomics in cancer.

Selected References Tusup M, French E.L., Guenova E, Kundig T, Pascolo S. Optimizing the functionality of in vitro transcribed mRNA. Biomed J Sci&Tech Res 2018;7(2).

Tusup M, Kundig T and Pascolo S. An eIF4G-recruiting aptamer increases functionality of in vitro transcribed mRNA. EPH - International Journal of Medical and Health Science 2018; 4(6):29-3.

Tusup M, Kundig T, Pascolo S. Epitranscriptomics of cancer. World J Clin Oncol 2018; 9(3):42-55.

Samaras P, Tusup M, Nguyen-Kim L, Seifert B, Bachmann H, von Moos R, Knuth A and Pascolo S. Phase I study of a chloroquinegemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology 2017;80(5):1005-1012.

30

Prof. Peter Schmid-Grendelmeier, MD Meike Distler, MD Eugen Bersuch, MD Benno Schnyder, MD Katrin Bänziger, MD Karin Grando Group Members and Associates Eugen Bersuch, MD Meike Distler, MD Kristina Tzekova, MD Christina Weber, MD Danielle Fehr, cand.med.

Karin Schnyder Muriel Trächsler

Main Fields of Research Our research activities are focused on epidemiology, pathophysiology and treatment of allergic diseases, namely atopic dermatitis. We also investigate new therapeutic options in a variety of diseases, mainly atopic dermatitis, mastocytosis and drug allergy. Recently we have also started to implement, evaluate and improve educational tools to promote knowledge and training in allergic diseases.

Selected References Franzen DP, Lang C, Agorastos N, Freitag L, Kohler M, Schmid-Grendelmeier P. Evaluation of Nickel Release from Endobronchial Valves as a Possible Cause of Hypersensitivity Pneumonitis in a Patient Treated with Bronchoscopic Lung Volume Reduction.

Int Arch Allergy Immunol. 2017;174(3-4):144-150 Bieber T, D’Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, Schmid-Grendelmeier P. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?

J Allergy Clin Immunol. 2017; 139(4S):S58-S64 Straub Piccirillo D, Schmid-Grendelmeier P, Hitzler M, Lauener R. Continuing medical education activities for improved management of allergy patients.

Allergy. 2018;73(6):1351-1353 Saulite I, Hoetzenecker W, Guenova E, Schmid-Grendelmeier P, Glatz M. Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.

Int Arch Allergy Immunol. 2017;174(3-4):190-199

31

7

Clinical research: UHZ Department of Dermatology, clinical trials unit (Lead: Dr. Sara Micaletto, PD Dr. Simone Goldinger, Prof. Reinhard Dummer)

PD Simone Goldinger, MD

Sara Micaletto, MD

Clinical research is a major focus at academic centers such as ours. It is essential to translate new basic research results into beneficial treatment regimens. Clinical trials today are performed within an increasingly regulated network that combines clinical, ethical, legal and economic aspects. Respect for the patient’s life and well-being and the integrity of all personnel involved (principles of good clinical practice) are absolutely critical. A network of clinical trial specialists is necessary so that clinical trials can be integrated into the treatment strategy for the respective disease.

The Department of Dermatology and the skin cancer unit have a long, successful record in this context. We are a major research center for the development of targeted therapies and immunotherapies for skin cancers and immune-mediated skin diseases.

Our center’s clinical trials unit has extensive experience in early and late phases of clinical development (phase I-IV). The unit is certified by SAKK to perform phase I trials and offers a post-graduate study in pharmaceutical medicine. The unit also has its own trial pharmacy.

Three dedicated trial pharmacists are part of the team and have established pharmaceutical management processes that have further elevated the level of quality for our trial patients.

In recent years, the clinical trial unit has worked with many molecules, including: – BRAF-inhibitors – MEK-inhibitors – Combination therapies with other kinase inhibitors including ribociclib – Anti-CTLA-4 antibodies

32

–

Anti-PD1 antibodies Combination of different immunotherapy agents including epacadostat and T-VEC Sting-Agonists, anti-LAG3 antibodies and anti-M-CSF antibodies Oncolytic virus therapy with T-VEC Pan-RAF inhibitors including RAF265, LXH254 – MDM2 inhibitors – Targeting T cell receptors for IMCgp100 – Somatostatin-analogons – Antisense-BCL-2 Nucleotides – Tyrosine kinase inhibitors including nilotinib, pazopanib, lapatinib and sorafenib – Gene therapy including T Vec Allovectin-7 and adenointerferon gamma and canary pox viral vectors – Pan-Kinase and Anti-VEGF inhibitors – Monoclonal antibody – Cytokine fusion proteins – Vaccines – Antimicrobial agents (taurolidine) – PEG interferon – Hedgehog Pathway Inhibitors – Histone-Deacetylase Inhibitors (HDAC) – RXR Retinoids – NAD+ biosynthesis inhibitors – Purine Nucleosid Phosphorylase inhibitors – Resiquimod – IL-17A and IL-17R antibodies – PDE4 inhibitors – TNF-α antagonists – IL-12/23 antibodies – IL-1β antagonists – IL1Ra soluble receptor – Topical parathormon – Topical Vitamin D3 analogons – Anti-IgE antibodies

We focus on the development of investigator initiated trials (IITs) for the treatment of orphan diseases of the skin and for sub-groups of skin cancer patients with high medical requirements, such as those with brain metastases.

Our clinical trial unit is now one of the leading clinical research centers in Europe Recognized as a SAKK Phase I Center on September 12, 2016, the UHZ dermatological clinical trial unit was officially approved by the Swiss Association for Clinical Cancer Research (SAKK) to conduct SAKK phase I/first in human (FIH) studies.

8

Research collaboration – Skintegrity and university research priority project, translational cancer research (URPP)

SKINTEGRITY – A flagship project on skin In autumn 2016, a new, large-scale interdisciplinary project under the University Medicine Zurich partnership was initiated with the aim of establishing our Zurich location as one of the world’s leading centers for skin research. The project is headed by S. Werner, Professor of Cell Biology at ETH, L. Sommer, Professor of Anatomy at the University of Zurich, and Prof. R. Dummer, Department of Dermatology, University Hospital Zurich, who replaced Prof. L. French from the Department of Dermatology at the University of Zurich (now Department of Dermatology at the University of Munich). The increasing relevance of skin diseases for the general population, such as skin cancer, chronic skin wounds and scleroderma, serves as the basis for this project. Through unique collaboration between highly specialized clinicians and scientists from the University of Zurich and ETH, the best expertise in biology, medicine, mechanics and engineering can be used to conduct rapid, targeted research with the aim of improving the treatment of severe skin diseases.

We focus on the development of innovative diagnosis and treatment of difficult or non-curable skin diseases, including chronic wounds, large burn wounds, scleroderma, lymphedema and epithelial skin cancers.

“SKINTEGRITY is unique in bringing together experts in clinical dermatology, rheumatology and surgery, basic researchers working on skin biology, and engineers. This has paved the way for various exciting projects that would otherwise not have been possible. These projects explore new ways to improve the diagnosis and treatment of major human skin diseases. The Department of Dermatology at University Hospital Zurich plays a central role in SKINTEGRITY and hosts the skin biobank, which is essential for all SKINTEGRITY projects.”

→ www.hochschulmedizin.ch/skintegrity

Prof. Sabine Werner, PhD. Citation

Program “Annual Event 2018”

33

University research priority project, translational cancer research (URPP) Since the launch of the university research priority project (URPP) for translational cancer research in 2012, the Department of Dermatology has served as a key contributing partner and has greatly benefited from the interaction and financial support provided.

The University of Zurich has committed more than CHF 6 million over a period of eight years to finance this URPP, with its primary aim being to bridge the gap between fundamental and clinical cancer research at the university. The URPP was directed by Prof. L. French until October 2018 (Successor: Prof. R. Dummer), supported by vice director Prof. K. Basler and scientific coordinator Prof. M. van den Broek.

The funding for URPP translational cancer research clearly underlines the commitment of our university with regard to promoting innovative cancer research based on high-quality science and translating it to the clinic.

URPP translational cancer research is unique in that it unites an exceptional team of internationally recognized scientists and physician scientists in the field of oncology and cancer research, and is committed to bridging the gap in communication and collaboration between physicians and scientists and thereby bringing cancer research a step closer to application in the clinic.

URPP translational cancer research focuses on the following four sub-projects: 1. Oncogenic signal transduction pathways as targets for personalized tumor therapy 2. Interaction between cancer and the human immune system 3. Tumor biopsy and live tumor cell biobank linked with clinical outcome data

In 2015, the performance of the URPP translational cancer research project was evaluated by three external experts commissioned by the university. Based on the very positive evaluation, productivity and outlook, the University of Zurich decided to continue the project in 2016 and increased financing by an additional CHF 11 million for the next four-year period (2017–2020).

The project facilitates innovation thanks to its dedicated post-doctoral fellows who liaise between clinical and basic labs and the high-level mentoring provided by the principal investigators in clinical and basic science.

As a consequence of the research strategy set out above, an increasing number of interesting publications have been prepared. One example is the collaborative work between the groups led by Prof. Sommer (Institute of Anatomy, University of Zurich), Prof. Levesque and Prof.

Dummer (both at the Department of Dermatology, UHZ) focusing on the control of melanoma growth and metastasis through the silencing of distinct tumor suppressors by the epigenetic modifier EZH2 (Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L.; Cancer Cell. 2018).

4. Translation from bench to bedside

→ www.cancer.uzh.ch

34

9

Research collaborations – foundations and associations

Bruno Bloch Foundation

One highlight on the Bruno Bloch Foundation calendar is its annual Memorial Lectures, which take place in February and are attended by more than 250 faculty members and students at UHZ. In 2018, Prof. Thomas Bieber, Chair of the Department of Dermatology and Allergy at the University of Bonn, held the Bruno Bloch Memorial Lecture.

The Bruno Bloch Foundation organized a charity recital with the exceptional contribution of Anne-Sophie Mutter for the first time in 2013. The funds collected served to finance research for skin diseases and skin cancer within the Department of Dermatology at UHZ. Important donors supported this charity evening and made a substantial contribution toward this research. Due to its success, the Bruno Bloch Foundation organized two other charity evenings – one in November 2015 with the participation of soprano Edita Gruberova and the Zurich Chamber Orchestra (ZKO) and one in May 2017 with the exceptional participation of the Béjart Ballet Lausanne. The next charity evening will be organized in 2020.

In 2015, the Board of Directors of the Foundation decided to grant two fellowships each year to young dermatologists (residents) from the Department of Dermatology at UHZ for further training abroad. Michael Kunz, MD, was awarded a fellowship in 2017 and joined the team led by Prof. John Paoli at Sahlgrenska Hospital in Gothenburg/ Sweden (research on skin cancer), and collaborated with several institutes in the USA, in particular with the MD Anderson Cancer Center in Houston (one of the largest cancer centers in the world). Julia-Tatjana Maul, MD, received the fellowship in 2018 and collaborated with the Skin Inflammation & Psoriasis International Network in South America.

From 2016, selected guests have been invited by the Bruno Bloch Foundation to attend its breakfast round table. At this event, a representative of the medical staff at the UHZ’s Department of Dermatology presents a specific topic of general interest in the field of dermatology to the audience. In 2017, Prof. Alex Navarini held a presentation titled “The Next Generation of Dermatology”.

The Bruno Bloch Foundation also organizes the yearly Zurich dermatology training days.

In autumn 2018, donators were invited by the Foundation to visit the Museum of Wax Moulages, which is managed by the University of Zurich and University Hospital Zurich (see also 14. Museum of Wax Moulages).

The Bruno Bloch Foundation offers its thanks to its generous donors and is proud to be able to support various research projects conducted by the Department of Dermatology at UHZ.

→ www.brunoblochstifung.ch

35

Association for Research on Cancer of the Skin (Verein für Hautkrebsforschung)

response (Nature Medicine, 2018). The molecular mechanisms of these observations will be further elucidated in the coming months.

Creation of a new position: skin cancer nurse

Founded in 2004, the Association for Research on Cancer of the Skin (Verein für Hautkrebsforschung; VHKF) aims to coordinate and stimulate skin cancer research in Switzerland by supporting the research of rare and severe forms of skin cancer (e.g. melanoma, cutaneous lymphoma, etc.). The board consists of Prof. R. Dummer (President), Prof. R. Braun, Prof. L. French and C. Frey-Blanc (treasurer), all of whom are based in Zurich, along with Prof. D. Hohl (Vice-President; based in Lausanne), Prof. R. Hunger (Bern), Prof. R. Kaufmann (Frankfurt) and Prof. W. Kempf (Zurich). The current goal is to generate a substantial contribution for clinical and experimental skin cancer research in Zurich and other institutions in Switzerland. Recently, the association created an assistant professorship position at the University of Zurich. Prof. M. Levesque, an internationally renowned melanoma researcher, will hold the position until he receives a full professorship with tenure track at the university. His research activities involve developing new tools for understanding next generation sequencing data, and performing functional tests of novel melanoma mutations in the laboratory. In this context, he is using the zebrafish as a model organism in order to improve the understanding of the biology of cancer genes.

In his new role, Prof. Levesque also manages the dermato-oncology biobank at UHZ, which provides a diverse collection of live cancer cells to collaborators for experimental research purposes. These are fundamental research activities that form the basis of understanding of melanoma progression, thereby enabling improvements to be made in melanoma therapy in the future.

In the past year, Prof. Levesque has also established a molecular tumor board for melanoma with the help of the ETH Nexus platform and an innovation grant from UHZ. This board will provide patients who have exhausted other therapy options with new possibilities based on the genomic sequence of their tumors and the availability of new targeted pathway inhibitors in the clinic. In addition, Prof. Levesque has obtained funding from the Skintegrity flagship project at ETH to continue to expand the dermatology biobank and make it more accessible to researchers across Zurich. Finally, collaborations with Roche and Bristol-Myers Squibb have led to further funding being provided in order to identify novel predictive biomarkers for melanoma immunotherapy treatment. These efforts have resulted in a publication that describes novel markers of circulating macrophages in patients receiving anti-PD1 inhibitors that were shown to have a predictive

36

Although significant progress has been made in the past few years thanks to the variety of treatment strategies in metastatic melanoma, physicians and patients may have overlapping or divergent expectations regarding the outcome of cancer therapies and the quality of the medical services provided. Despite this, virtually no communication takes place between physicians and patients in this regard.

Sandra Fluri Skin Cancer Nurse

The role of nursing in systemic therapy should be mentioned here. As of October 2016, a specialist skin cancer nurse position – financed by the Association for Skin Cancer Research (Verein für Hautkrebsforschung) – has been integrated into the treatment processes and is responsible, in particular, for regular contact with patients regarding adverse events (AE), which can occur at any time during treatment. Many patients find it easier to phone a nurse than a doctor; nurses can therefore serve as an approachable liaison between the patient and the treatment team. For this position, the nurse must be familiar with the specific AE spectrum and the timing of AEs during therapy.

→ www.skincancer.ch Christine Kühne Center for Allergy Research and Education (CK-CARE)

The Christine Kühne Center for Allergy Research and Education (CK-CARE) is dedicated to the research and education of allergic diseases with a specific focus on atopic dermatitis. Founded in Davos in 2009, it has led to the creation of a network of research groups in Davos, Bonn, Munich, St. Gallen and the UHZ’s allergy unit (see www.ckcare.ch). In the intervening decade, this foundation has become part of a larger initiative with a broad focus on various allergic diseases, with the Allergy Campus Davos serving as the nucleus.

→ www.ck-care.ch

10

Collaborations with other dermatology centers

a. Close collaborations including staff rotations/ exchanges with Kantonsspital Thurgau AG, Kantonsspital Winterthur, Kantonsspital Graubünden, Hochgebirgsklinik Davos and Zuger Kantonsspital

Kantonsspital Thurgau AG: dermatological outpatient clinic at Kantonsspital Frauenfeld

A dermatological outpatient clinic at the Kantonsspital Frauenfeld (cantonal hospital; KSF) has been in operation since 2011, and works in close collaboration with the UHZ Department of Dermatology. The clinic is run by two senior dermatologists from the Department of Dermatology who divide their hours between UHZ and KSF. The team of physicians receives support from a senior dermatology resident from UHZ who is sent to Frauenfeld for a sixmonth rotation. Dr. St. Nobbe currently serves as head of the clinic. Other senior dermatologists who have held positions at the clinic include Dr. L. Wiederkehr (May 2016– June 2017), Dr. P. Kraenzlin (June 2017–August 2018) and Dr. A. Frauchiger (since September 2018).

Kantonsspital Winterthur

Kantonsspital Winterthur has overseen a dermatology and allergy outpatient clinic for several years now.

Chaired by Dr. Marianne Lerch, its services are provided in close collaboration with the Department of Dermatology at UHZ. Dr. Lerch teaches students at UHZ, while a senior physician position is shared between the two institutions (currently filled by Dr. Carla Murer).

Kantonsspital Graubünden, Chur

A dermatology service based on a cooperation model with UHZ has been provided at Kantonsspital Graubünden in Chur since 2017. This service is overseen by Dr. Carina Butzmann, a FMH-certified specialist in dermatology and venereology. She works at both institutes, which facilitates a close professional exchange with the UHZ’s Department of Dermatology. Dr. Butzmann’s expertise covers a wide range of dermatological diseases, including pediatric skin diseases. The service is in high demand and works to meet the requirements of referring doctors and other departments at the hospital. Dr. Butzmann has also established a CME circle for local dermatologists, during which talks are provided by external experts and experiences of own cases are exchanged.

→ www.ksgr.ch Hochgebirgsklinik Davos

The clinic covers a broad range of outpatient dermatology services and has a radiotherapy unit. The majority of patients are referred by practicing physicians. In addition, the clinic is responsible for dermatological inpatient consultations for all hospitals in the canton of Thurgau. Special consultation hours are held on a monthly basis with professors from UHZ.

UHZ works very closely with Hochgebirgsklinik Davos and CK-CARE, both of which are members of the Health and Life Science Campus in Davos. The Kühne Foundation was responsible for establishing an Allergy Competence Center with new research and educational facilities. There are special programs for patients with allergic and inflammatory skin diseases and food intolerances (especially histamine intolerance). Special programs involving a high level of patient care paired with specific educational programs and nutritional and psychosomatic support result in a unique hospitalization experience in a special setting with

37

fully renovated private rooms. In addition to medical care, collaboration includes training and teaching exchanges for medical doctors, students and allied health programs.

→ www.hochgebirgsklinik.ch Zuger Kantonsspital, Baar

In close connection with the Department of Dermatology at UHZ, Dr. Elisabeth Hohenstein Jaccard runs a two-day dermatology service at Zuger Kantonsspital for outpatients who have been referred and internal consultancies.

Prof. Peter Schmid-Grendelmeier oversees this service on the part of UHZ and, together with PD Dr. Martin Glatz, serves as an external consultant for allergic diseases at Zuger Kantonsspital.

→ www.zgks.ch b. Partnership with other dermatology centers in Switzerland

Kantonsspital St. Gallen; Department for Dermatology, Venereology and Allergology

The development of the new Department for Dermatology, Venereology and Allergology at Kantonsspital St. Gallen continued to gain momentum in 2018. The allergology department in particular received a significant boost thanks to the appointment of Prof. Barbara Ballmer-Weber as head physician ad personam. On May 4, 2018 – as part of a symposium to mark the opening of the clinic – we presented the new clinic building in House 20 to approximately 200 participating Swiss dermatologists. In the first year alone, the number of outpatients with the clinic’s new B-training status has increased by more than 20% to approximately 19,000 visits. In September 2018,

38

250 national and international skin lymphoma specialists attended our international congress as part of the EORTC-CLTF (Cutaneous Lymphoma Task Force) in St. Gallen (co-organized with PD Dr. Emmanuella Guenova, UHZ, and Prof. Werner Kempf, Zurich). The clinic presented Swiss dermatology as an innovative specialist field with an excellent supporting network.

11

Medical education and training

Medical education is essential for guaranteeing a high level of professionalism among physicians and healthcare professionals. Our continued commitment to education is reflected by: 1. Student education at the University of Zurich’s medical faculty.

2. Specialist training for resident physicians qualifying in dermatology and venereology, and allergology, clinical immunology and phlebology.

3. Ongoing medical education for private practitioners – primarily dermatologists and allergologists, as well as general practitioners and (to a lesser extent) other healthcare professionals.

Student education Senior physicians at our department provide an introductory dermatology course for third-year medical students, a yearly core course in dermatology (as part of an eightday block) for fourth-year medical students, and a casebased thematic lecture series and a practical training course in dermatology in the sixth year of the medical training curriculum at the University of Zurich. ETH Zurich has offered a curriculum for a Bachelor’s degree in medicine since 2017. As part of this program, several members of our department are involved in teaching introductory modules in dermatology, immunology and allergology.

These ex-cathedra and bedside teaching activities are complemented by web-based learning modules involving an online platform (Dermatology Online with Interactive Technology; DOIT), which was developed by our department under the direction of former chairman Prof.

Gunter Burg in close collaboration with several other dermatology departments (Basel, Bern, Lausanne, Jena, Stadtspital Triemli in Zurich and the European Dermatology Forum; see also www.cyberderm.net).

This platform has been further improved under the direction of Prof. Peter Itin with the support of the European Dermatology Forum and is currently available in seven languages with two further languages scheduled.

In 2009, the DOIT platform was chosen as the best internet-based teaching platform and won the Medida Prize (worth EUR 50,000).

In addition to a host of lectures and courses, a new course on translational allergy was launched with great success in 2017. Held at Hochgebrigsklinik Davos, this course has become highly popular in the meantime and is rated as “very useful” by the participants.

Resident physicians The Department of Dermatology at UHZ is a training site for specialization in dermatology/venereology, according to the training program approved by the Swiss Institute of Medical Education (SIME-SIWF). Four of the requisite five years of dermatology training can be completed on site.

Resident candidates must fulfill the following requirements: – Two years of medical training at a Swiss hospital: either two years of internal medicine or one year of internal medicine and one year of surgery.

– Finalized or pre-finalized MD thesis.

Our staff provides opportunities to conduct scientific work alongside an MD thesis.

Three training positions are also available that cover part of the board certification in allergology and clinical immunology and angiology. During their residency training in our department, residents benefit from the most comprehensive program in Switzerland, comprising a rotation plan of 20 units and specialist clinics covering all subspecialties of dermatology and allergology, including dermato-oncology, autoimmune skin disease, trichology (hair disease), dermatosurgery, dermatopathology, physical skin therapy (radiotherapy, UV therapy, laser therapy), phlebology and others.

In addition, three residency positions are available at the allergy unit for board certification in allergology and clinical immunology. These positions count for the full three years that are required in a specialist clinic to obtain the FMH qualification. The quality of the training and teaching receives a very high rating among residents.

39

Guest Speakers 2017/2018 Speaker

Institution Topic

Krasovec Rahmann Marguerite, MD

Private Dermatologische Praxis, Schlieren, CH

Anuläre Dermatosen – Fälle aus der Praxis; Aus der Praxis: Standespolitisches; Dermatosen der Intertrigines

Krunic Alexander, Prof.

Northwestern University Feinberg School of Medicine, River Forest, IL/USA

Case series: Moh’s surgery in rare tumors

Kucher Nils, Prof.

Klinik für Angiologie, Universitätsspital Zürich, CH

Postthrombotisches Syndrom

Lallas A

First Department of Dermatology Aristotele University Thessaloniki, Greece

Spitz nevi and Spitzoid lesions; Dermatoscopy in general Dermatology (Lichen planus, Psoriasis etc.)

The Institute of Cancer Research, Royal Marsden London, UK

New Perspectives in Immuno-Oncology – Treatment Considerations & Treatment Choices for RCC and Melanoma

Laubach Hans-Joachim, MD

Service de dermatologie, CHUV, Genf, CH

Laser and EBD safety

Lautenschlager Stephan, Prof.

Dermatologisches Ambulatorium, Stadtspital Triemli, Zürich, CH

Sonnenschutz; Häufige und seltene Infektionen durch Dermatophyten

Leiter Ulrike, PD Dr. med.

Universitäts-Hautklinik Tübingen, DE

Prognostische und therapeutische Konsequenzen eines positiven Sentinel-Nodes

Levy Jean-Luc, MD

Service de Dermatologie, CHUV, Lausanne, CH

Introduction into clinical use of different lasers and EBDs

Luder Claude, MD

Dermatologische Klinik, Stadtspital Triemli, Zürich, CH

Livedo-Vaskulopathie

Mahler Daniel, MD

Private Dermatologische Praxis, Luzern, CH

Aktuelles zum Tarif/TARMED/TARCO

Marghob Ashfaq A., Prof.

Memorial Sloan-Kettering Skin Cancer Center, Long Island, NY, USA

Benign melanocytic lesions (including congential nevi); Total Body Imaging; Melanoma

Marini Leonardo, Prof.

Skin Doctors Center, Trieste, IT

Pre- and post-procedure care

Maurer Marcus, Prof.

Klinik für Dermatologie und Allergologie, Charite Berlin

Management der Chronischen Urtikaria

Meier Thomas, PD Dr. med.

Klinik für Angiologie, Universitätsspital Zürich, CH

Endovenöse Thermoablation

Mohr Peter, MD

Klinik für Dermatologie, Elbe Klinikum Buxethde, DE

Adjuvante Therapie des Melanoms

Mühlstädt Michael, MD

Servcie de Dermatologie et Vénérologie, Hôpital Universitaire Genève, CH

Liposarkom

Larkin James, MD

40

Guest Speakers 2017/2018 Speaker

Institution Topic

Müller Nicolas, MD

Klinik für Infektiologie und Spitalhygiene, USZ, Zürich, CH

Zika- und Arboviren

Müller Simon, MD

Dermatologische Klinik, Universitätsspital Basel, CH

Das Kreuz mit den Kreisen

Plaza Tobias, MD

Private Dermatologische Praxis, Uster, CH

Systemtherapie und Biologics bei Psoriasis für praktizierende Dermatologen; Systemtherapie und Biologics bei Psoriasis und Hidradenitis suppurativa für praktizierende Dermatologen; Qualitätsmanagement in der Dermatologischen Praxis; Phototherapie (UV+PDT) in der Praxis

Rast Hanspeter

Arbeitsmedizin und Dermatologie, SUVA, Luzern, CH

Kasuistiken zur Berufsdermatologie

Reutter Daniela, MD

Klinik für Angiologie, Universitätsspital Zürich, CH

Lymphödem

Robert Caroline, Prof.

Institut Gustave Roussy, Villejuif, F

Advances in Melanoma Therapy

Rümmelein Bettina, MD

Private Dermatologische Praxis, Kilchberg, CH

Neues zur Faltentherapie; Laser-supported PDT: Indikation, Technik, Ablauf und Ergebnisse

Salmhofer Wolfgang, Prof.

Universitätsklinik für Dermatologie und Venerologie, Graz, A

Duplex Ultraschall

Schiestl Clemens, PD Dr. med.

Zentrum für brandverletzte Kinder, Plastische und Rekonstruktive Chirurgie, Kinderspital Zürich, Zürich, CH

Wie kultivieren wir einen Hautersatz?

Schlappbach Christoph, Prof.

Universitätsklinik für Dermatologie, Inselspital, Bern, CH

Neues zur Pathogenese: Psoriasis

Schuster Christian, MD

Private Dermatologische Praxis, St. Gallen, CH

Tarifeingriff durch Bundesrat: Gründung der “Interessengemeinschaft für Qualität in der Dermatologie, IQD”

Schlüer Anna-Barbara, MD

Dermatologie, Kinderspital Zürich, CH

Praktische Anwendung von Salben und Verbänden bei atopischer Dermatitis

Signer-Brandau Doris

Psychotherapeutische Praxis, Zürich, CH

Umgang mit schwierigen Patienten

Stingl Georg, Prof.

Universitätsklinik für Dermatologie, Medizinische Universität Wien, A

Ekzeme-Klinik Differentialdiagnose Pathogenese & Therapie

Surber Christian, Prof.

Department of Dermatology, Universitätsspital Basel, Basel, CH

Schmieren und Salben hilft allenthalben

41

Guest Speakers 2017/2018

42

Speaker

Institution Topic

Terrani Isabella, MD

Servizio die Dermatologia Ente Ospedaliere Bellinzona, CH

Candida assoziierte Hautmanifestationen

Therheyden Patrick, Prof.

Universitätsklinikum Schleswig-Hohlstein, Lübeck, D

Biologie und Therapie des Merkelzellkarzinoms

Thomas Luc, Prof

Centre Hospitalier Universitaire de Lyon, F

Basal cell carcinoma; Lesions of the face; Dermatoscopy of Nail Pigmentations; Sequential Imaging

Trüeb Ralph, Prof.

Dermatologische Praxis und Haarcenter, Wallisellen, CH

Haare im Alter

Volz Andreas, MD

Dermatologische Klinik, Universitätsspital Basel, CH

Chirurgie (What’s New Session)

Wentel Tim, MD

Dermatologische Klinik, Ceulen Klinieken, NL

Endovenöse Thermoablation

Wörle Brigit, MD

Lipödem Zentrum Zentralschweiz LZZ & Hirslanden Klinik, Meggen, CH

Lipödem 2018

Zbinden Reinhard, Prof.

Institut für Medizinische Mikrobiologie, Universität Zürich, CH

STI und Resistenzen

12

Congresses/ scientific meetings

Zürcher Dermatologische Fortbildungstage 2017 / 2018 The Zürcher Dermatologische Fortbildungstage (ZDFT) were launched in 2011 and immediately proved to be highly successful, as reflected in the feedback and number of participants (primarily practicing dermatologists).

At last count, this figure stood at more than 240 physicians, thus confirming that this event is one of the most important dermatology congresses in the Germanspeaking region of Switzerland.

The three-day intensive event for ongoing medical training offers a mix of plenary lectures and hands-on workshops at the Department of Dermatology, and a half-day session titled “What’s new?”. Each congress centers on an annual theme, which is addressed by a number of international speakers. In 2017, the theme was “(Rare) Skin Tumors and Tumor Syndromes”, while in 2018 it was “Vascular Disorders”. Both subjects proved to be engaging and enriching, including among practitioners in dermatology. For the 2018 edition, four workshops were held for medical practitioner assistants (MPA) and were overseen by our nursing/MTRA and physician team.

The event in 2017 marked the first time that all presentations were made available on the website free of charge. They could be accessed by participants and other interested parties for a period lasting approximately one year, thus providing the opportunity to continue to explore the subjects presented long after the end of the congress.

Interesting, interactive exchanges of this kind between our team and our speakers may motivate us to expand this format for medical education to other locations in future.

→ www.zhdermfortbildungstage.ch

43

41st Annual Meeting of the Arbeitsgemeinschaft für Dermatologische Forschung, March 8–10, 2018, Zurich From March 8 to 10, 2018, the 41st Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) took place in Zurich. This marked the first time in 17 years that this important German research conference has been held in Switzerland. It was very well attended with more than 400 participants, while the local symposium on “Precision Medicine in Dermato-Oncology” led by PD Dr. Emmanuella Guenova and Prof. Reinhard Dummer attracted a great deal of interest in particular.

Other selected meetings SGDV Fostering course in dermatology/phlebology, March 2018 Phlebology and wound management are two traditional mainstays of dermatology and venereology. Tumescent local anesthesia, ambulatory phlebectomy and endovenous laser thermal ablation are all milestone procedures that have originated from the field of dermatology, as have innovations in compression therapy, shave therapy for venous ulcers, and further research in wound healing.

Despite these breakthroughs, the importance of phlebology within dermatology has declined in recent decades.

Now is a prime opportunity to introduce the latest generation of dermatology residents to this attractive subspecialty.

For this occasion, the Department of Dermatology at UHZ put on its first fostering course on phlebology and wound management on March 23 and 24, 2018, under the auspices of the Swiss Society of Dermatology and Venereology. The course consists of five theoretical and corresponding practical modules that cover the entire field.

44

Tutors: Hafner J, Kockaert M, Buset C, Conde-Montero E, Salmhofer M, Wentel T

The forty participants – primarily from Switzerland with a few representatives from other EU countries – were highly motivated, with the course receiving excellent feedback and ratings as a result. The second edition will take place on February 1 and 2, 2019. The plan is to integrate the course into the popular Venalpina meeting in 2020.

→ www.zhdermfortbildungstage.ch

SGDV 10th & 11th International Dermatoscopy Course, September 21, 2017 and September 27, 2018

Basic course in laser technology (Organization: Laurence Imhof, MD), December 2018

The annual 10th and 11th SGDV International Dermatoscopy Course (chair: Prof. R. Braun) took place in Zurich at UHZ in September 2017 and 2018. Attended by more than 220 participants, the course featured an array of international speakers, including Prof. Dr. Ashfaq Marghoob (New York, USA), Prof. Dr. Luc Thomas (Lyon, France) and Prof. Dr. Aimilios Lallas (Thessaloniki/Greece).

On December 7, 2018, the first basic course in laser technology (FMCH credits) was held at the Careum Auditorium in Zurich (chair: Dr. Laurence Imhof). The aim of the course was to prepare the participants (physicians) for the FMCH basic course in laser technology exam.

Contributors from Switzerland included Dr. Oliver Gaide (CHUV/Lausanne) and Prof. Robert Hunger (Bern).

All speakers helped to ensure interesting, enriching and, above all, high-quality dialogue at international level.

The 32 participants greatly appreciated the highquality, boutique-style course, personal coaching and plenary sessions as part of different workshops with the following external experts: Dr Hans-Joachim Laubach (Geneva), Dr. Jean-Luc Levy (Lausanne), Prof. Leonardo Marini (Trieste/I), Prof. Reinhard Dummer and Dr. Laurence Imhof.

Allergy Training Course for Dermatology Residents in Training 2017 and 2018 For the second time, we organized a two-day interactive allergy course for residents in training together with CKCARE. The course included practical tasks such as skin prick tests and anaphylaxis management. Case-based discussions and workshops combined with short online teaching videos were used to familiarize the residents with allergic conditions such as inhalant, food and hymenoptera allergies as well as allergy-related skin diseases such as atopic dermatitis, contact dermatitis, urticaria and mastocytosis.

Our external speakers: L. Marini, J.-L. Levy, H.-J. Laubach & L. Imhof

45

13

Public relations

Events for the public and patients We regularly organize evening events on topics such as psoriasis, neurodermatitis, rosacea, acne and acne inversa, and provide information on skin cancer during National Swiss Cancer Day in May. These evenings are highly popular, and are usually attended by around 200 participants.

Experten der Dermatologischen Klinik informieren

Neurodermitis? Kein Grund zum Verzweifeln

Veranstaltung für Betroffene und Angehörige Dienstag, 17. April 2018, 18.00 – 19.00 Uhr Grosser Hörsaal Ost UniversitätsSpital Zürich

Wir wissen weiter.

k Dermatologische Klini

Patient information brochures for specific illnesses Hidradenitis suppura (Acne inversa)

tiva Dermatologische Klini k

We edit our own patient information brochures about the most common skin diseases, such as skin cancer, neurodermatitis, psoriasis, hand eczema, acne inversa, laser medicine and others, with the intention of providing balanced, objective information to our patients. These are free of charge, available from our website and regularly ordered by practicing dermatologists for distribution to patients.

Patienteninformation

Das Melanom oder schwarzer Hautkrebs Patienteninformation

46

58

Tages-Anzeiger – Samstag, 3. September 2016

Internet/intranet/social media/ media relations

Wochenende Wissen Treffen mit Peter Schmid-Grendelmeier, Dermatologe und Leiter der Allergiestation des Universitätsspitals Zürich

Professor Sushi

We regularly update our pages on www.dermatologie.usz.ch to ensure that we deliver the latest and most accurate content possible. We also provide blog posts for social media where appropriate.

Um bessere Therapien zu entwickeln, geht Allergologe Peter Schmid-Grendelmeier auch unkonventionelle Wege. So plante er etwa schon den Einsatz von Hakenwürmern, einem Parasiten.

Stefan Müller Kaum tritt der Professor vor seine Bürotür, wird er von einer Patientin angesprochen. Sie hat sich in den Gängen der Dermatologischen Klinik des Universitätsspital Zürich verirrt und erwartet vom erstbesten Weisskittel Hilfe. «Vor zehn Jahren wurde hier der Portier aus Spargründen abgeschafft, seitdem finden sich die Patienten nur noch schlecht zurecht», erklärt Peter Schmid-Grendelmeier, Leiter der Allergiestation, mit einem Augenzwinkern.

Mit seiner dunklen Hornbrille, dem Schalk in den Augen und seiner unprätentiösen, umgänglichen Art entspricht Peter Schmid-Grendelmeier, der bei unserem Treffen in einem kleinen, wenig repräsentativen Büro sitzt, keineswegs dem Bild eines abgehobenen Professors. Der Dermatologe hat sich mit der Erforschung von Neurodermitis und Allergien in der internationalen Fachwelt einen Namen gemacht. So wies er kürzlich in einer wegweisenden Studie nach, wie ein verbreiteter Pilz auf der Hautoberfläche die Entzündung bei Neurodermitis fördert und mit einer simplen Pilzbehandlung in Form von Tabletten die Beschwerden deutlich gelindert werden können. «Der Hefepilz kann mit der Haut und dem Immunsystem interagieren, weil bei Neurodermitis die Barrierefunktion der Haut beeinträchtigt ist», erklärt Schmid-Grendelmeier.

Sushi kann Allergien auslösen. Foto: iStockphoto

Aus wenig Mitteln das Optimale zu machen, lernte er in Afrika.

Allergiestation mit seinen rund 30 Mitarbeitenden, die er seit dreizehn Jahren innehat. Seine Erfahrungen in Afrika empfindet er heute als gute Vorbereitung für das Führen eines Betriebes – «aus wenig Mitteln das Optimale herauszuholen», konstatiert er. Auch die klinische Lehre, die Schulung von Patienten oder Hausärzten, liegt ihm sehr am Herzen.

Mehr Dreck statt Hygiene

Wurm im rohen Fisch

Besonders interessiert ihn aber auch, wie Parasiten Einfluss auf das allergische Geschehen nehmen.

«Diese Vorliebe trug mir den humoristischen Spitznamen Professor Sushi ein», bemerkt Schmid-Grendelmeier schmunzelnd. Den «Ehrentitel» erwarb er sich an einem Kongress in Deutschland. Er berichtete dort von einem Rega-Arzt, der wiederholt nach Südostasien gereist ist und an einer Sushi-Allergie leidet, ausgelöst durch den Heringwurm, der im rohen Fisch vorkommt. Nach einer Wurmtherapie und dem Meiden des Wurms lebt der Arzt beschwerdefrei. In diesem Fall löste der Parasit eine Allergie aus. Umgekehrt weiss man aber auch vor allem aus Drittweltländern, dass das Immunsystem von Menschen mit Parasitenbefall gedämpft ist und somit auch die allergischen Reaktionen.

Vor rund drei Jahren wollte er dieser Wechselwirkung genauer auf den Grund gehen. Er konzipierte eine Studie mit Hakenwürmern. Von diesem Parasiten ist aus der empirischen Forschung bekannt, dass er das Immunsystem unterdrückt und zugleich relativ harmlos ist. Das Unappetitliche an dieser Studie ist jedoch, dass die Wurmeier über die Haut dem Körper zugeführt werden müssten.

Die Ethikkommission verhinderte die Durchführung der Studie. «Weil der Wurm im Körper nicht kontrollierbar und die Sicherheit dadurch nicht gewährleistet ist», erklärt Peter Schmid-Grendelmeier. Der «Wirkstoff» des Wurms, der mit dem Immunsystem interagiert, müsste isoliert und steril hergestellt werden können. Bis dahin ist es allerdings noch ein weiter Weg, den Schmid-Grendelmeier trotzdem weiterverfolgt.

«Eigentlich wollte ich Tropenarzt werden», erinnert er sich, den andere Kulturen und Länder schon immer faszinierten. 1997 hatte er dann jedoch die

delmeier, dessen Studie zur Teledermatologie als Pionierarbeit gilt. Heute pflegt er weiterhin regen Kontakt mit Fachkollegen in Tansania, wo Allergien genauso verbreitet sind. Einmal pro Jahr besucht er das Land. Mit seinem Afrika-Fieber vermochte er schon hiesige Berufskollegen anzustecken, die ihn mittlerweile auch regelmässig begleiten, auch auf seine beliebten Safaris.

Was fasziniert Peter Schmid-Grendelmeier eigentlich an der Allergologie? «Im Lauf der Zeit merkte ich immer mehr, wie sehr das Fachgebiet auf mich als vielseitig Interessierten zugeschnitten ist», sagt er. Allergologie sei das ideale Bindeglied zu Fächern wie Umwelt, Tiere, Essen oder anderen medizinischen Bereichen. Als begnadeter Kommunikator passt ihm auch die Leitungsaufgabe in der

Seit seinem Einstieg in die Allergologie hat sich in diesem Fachgebiet viel geändert. Allergien nehmen in allen Industriestaaten von Jahr zu Jahr zu. Einstige Gewissheiten sind obsolet geworden, wie zum Beispiel: Meiden, was man nicht verträgt. Heute gilt eher das Gegenteil. So lautet die Empfehlung, Babynahrung soll im ersten Lebensjahr möglichst vielfältig sein. Dies soll das Risiko senken, an einer Neurodermitis oder an Asthma zu erkranken.

Moderne Prävention lautet heute: mehr Dreck statt Hygiene. Eine wirksame Behandlung steht mit der Desensibilisierung zur Verfügung. Gezielt werden dabei Allergene in sehr geringen Dosen unter die Haut gespritzt, um das Immunsystem zu trainieren, sodass eine Gewöhnung eintritt und eine allergische Reaktion unterbleibt. Weil diese Therapie sehr aufwendig ist, arbeitet man daran, sie zu optimieren, zum Beispiel mit der Gabe der Allergene unter die Zunge mittels Tabletten, was bei Heuschnupfen schon recht erfolgreich ist.

Zunehmend verbreitet sind aber auch Nahrungsmittelallergien oder -unverträglichkeiten. Die Lebensmittelindustrie hat den Wink verstanden und überschwemmt den Markt mit entsprechenden Produkten, die die Ängste der Menschen bedienen: «Frei von»-Lebensmittel boomen, ob ohne Allergene wie Nüsse oder ohne Gluten. «Das Geschäft blüht – die Verunsicherung der Patienten wächst», stellt Schmid-Grendelmeier fest.

Wenn Professor Sushi sich einmal nicht gerade den Würmern widmet, findet er gelegentlich auch Zeit, an einem Kurz-Triathlon teilzunehmen – «vom Ironman träume ich», gesteht er leise ein. Er ist sich indes bewusst, dass er dieses Ziel nie erreichen wird. Der Schnauf mag Peter Schmid-Grendelmeier beim Ironman ausgehen, nicht aber bei seiner Forschung, die er unablässig vorantreibt.

anderes, bis diesem die Luft wegbleibt, oder es presst dem Gspäändli den Brustkorb zusammen, oder Gürtel, Handtücher, Vorhänge, Schuhbändel

klickt. Was die Youngster meist nicht wissen: Durch den Sauerstoffmangel sterben Hirnzellen ab, es kann zu epileptischen Anfällen kommen,

«Eigentlich wollte ich Tropenarzt werden», sagt Peter Schmid-Grendelmeier. Foto: Thomas Egli

Möglichkeit, als dermatologischer Konsiliararzt und Lehrbeauftragter ans Regional Dermatology Training Center in Tansania zu gehen. Sein Arbeitsplatz in Moshi war ein Spital mit rund 600 Betten am Fuss des Kilimandscharo. Da seine Frau als Laborantin im selben Spital arbeitete, lebten sie mit ihren beiden Kleinkindern zwei Jahre in Afrika.

Die weiten und schlecht erschlossenen Landstriche Tansanias brachten den inzwischen Kisuaheli sprechenden Schweizer Arzt auf die Idee, die medizinische Versorgung mithilfe der damals noch neuen Teledermatologie zu verbessern. Weil dabei Bilder von der Haut eines Patienten einfach via Internet in ein fernes Spital übermittelt werden, entfällt der Arztbesuch. «Das Internet stand damals erst rudimentär zur Verfügung», sagt Schmid-Gren-

Medizinisches Kabinett Von Martina Frei

Tödliches Würgespiel Manchmal ist es gut, wenn Eltern wissen, was ihre Kinder spielen. Die Mutter

Our team of senior consultants is at the service of the media (standard and specialist press) for targeted subjects/interviews on a regular basis.

der war um seinen Nacken gewickelt. Der «Glasgow Coma Scale», ein Mass für den Schweregrad eines Komas, betrug noch 3 von maximal 15 Punk-

47

14

Museum of Wax Moulages

Each year, more than 300 medical students attend basic dermatology and venereology courses at the Museum of Wax Moulages in Zurich. They then revisit the collection later in order to refresh their knowledge and prepare for their final exams. For many universities of applied sciences, a visit to the museum has become part of the curriculum for students in healthcare. The museum, which contains three-dimensional life-sized and lifelike exhibits of skin diseases alongside the history of the patient in a contemporary context, also lends itself to interdisciplinary studies, e.g. the UHZ CAS MedLaw program.

Interest in the public museum is growing all the time, and special events are regularly held that focus on new and different aspects of the museum’s collection of historical teaching aids and research documents. During the Long Night of Museums in 2017, well-known local artists used the more than 800 visitors as the basis for drawing and painting minor disfigurements as a means of spotlighting the artistic aspects of the wax moulages and encouraging discussion surrounding how we perceive “flaws”. The 2018 edition was even more successful, attracting more than 900 people to the museum’s exhibition on exotic diseases.

The museum is a popular destination for meetings and events for many different societies and other groups.

One such society is the Bruno Bloch Foundation, whose donators visited the museum in 2018 and subsequently decided to support the research performed at the Museum of Wax Moulages in the form of a grant.

Michael Geiges (curator) and Sabina Carraro (restorer) are active with projects concerning academic teaching and medical historical research, and place special emphasis on the improvement of conservation and restoration. In collaboration with the Institute of Evolutionary Medicine at UZH, the team was able to produce a repaired duplicate of a broken historical moulage using modern 3D technology and the traditional manner of moulage production without requiring the original wax object to be touched.

→

48

For more information about the museum, please visit www.moulagen.ch

Michael Geiges, MD, Curator of the Museum of Wax Moulages, and Patrick Schaffter, Administrative Director of the Bruno Bloch Foundation, at the Museum of Wax Moulages

15

Promotions, grants, honors and awards

Promotions

FMH board exam (specialist examinations)

Professorship ad personam – Prof. Thomas Kündig was appointed Associate Professor ad personam for immunodermatology at the University of Zurich’s Faculty of Medicine on January 30, 2017 (with simultaneous employment as senior physician and Head of the Dermatology Polyclinic at University Hospital Zurich).

– Prof. Mitchell Levesque was appointed Extraordinarius ad personam for dermatological skin research in June 2017.

FMH Board Exam, Dermatology and Venereology 2017: Dr. Florian Anzengruber, Dr. Anna Frauchiger, Dr. Omar Ali Hassan, Dr. Nicoletta Jaberg-Bentele, Dr. Fabrice Kaufmann, Dr. Julia-Tatjana Maul, Dr. Selina Thurneysen, Dr. Regula Brändli 2018: Dr. Marie-Charlotte Brüggen, Dr. Claudia Lang, Dr. Caroline Guillod, Dr. Samuel Conrad (employed until 2018)

Adjunct Professorship – Prof. Pål Johansen was appointed Adjunct Professor of Immunology and Allergology at the University of Zurich by the extended university administration in June 2017.

Venia legendi 2017 and 2018 PD Hans-Dietmar Beer, PhD; PD Philipp Bosshard, PhD; PD Emmanuel Contassot, PhD; PD Martin Glatz, MD; PD Simone Goldinger, MD; PD Beda Mühleisen, MD Head of Nursing; member of the Executive Board, Department of Dermatology, UHZ Sandra Beeler, former head of the Department of Dermatology’s outpatient clinic, has been Head of Dermatology care since October 1, 2017. She remains closely involved in formulating the maintenance procedures for the planned UHZ airport.

Attending physicians with extended responsibility Prof. Dmitry Kazakov, MD; PD Emmanuella Guenova, MD, PhD; Laurence Imhof, MD; Stephan Nobbe, MD Attending physicians F. Anzengruber, MD (July 2018), Carina Butzmann, MD ( October 2017), Nadia Galliker, MD (May 2017), Nora Gräni, MD (May 2017), Daniella Jenni, MD (October 2017), Pascale Kränzlin-Stieger, MD (July 2017), Sara Micaletto, MD (August 2018), Maya Wolfensperger-Ziegler, MD (May 2018) Re-entry as attending physicians PD Emmanuella Guenova, MD, PhD, attending physician with extended responsibility (as of July 1, 2017), Isabel Kolm-Djamei, MD (as of September 2018)

FMH Board Exam, Allergology and Clinical Immunology Dr. Eugen Bersuch, Dr. Sabine Bruckert, Dr. Antonios Kolios, Dr. Nadja Galliker, Dr. Caroline Guillod, Dr. Susann Hasler, Dr. Claudia Lang, Dr. Iryna Yastremska International dermatopathology board exam, 2018 Dr. Mathias Drach, Dr. Isabel Kolm-Djamei Acceptance of managing physician positions at other medical/university departments in Switzerland and abroad – Prof. Barbara Ballmer-Weber, MD (2018): Head of Allergy Division, Department of Dermatology and Allergology, Kantonsspital St. Gallen – Prof. Lars French, MD (2018) 2018: Appointed chairman at Ludwig- Maximilian University of Munich (LMO) as of November 1, 2018.

Succeeded Prof. Thomas Ruzicka (retired) at the Clinic and Polyclinic of Dermatology and Allergology; In addition, Prof. French has taken over management of “Derma I” with 110 beds in the University Hospital of Munich’s Department of Dermatology and Allergology.

The department’s outpatient skin clinic is the largest of its kind in Europe and is maintained by the University Hospital of Munich. The inpatient clinic (focusing on dermatology) is part of the medical center of the city of Munich.

– PD Wolfram Hötzenecker, MD (2017): Head (primarius) of the Department of Dermatology and Venereolgy, Kepler University Hospital, Linz – Prof. Alexander Navarini, MD, PhD (2018): Head of Department of Dermatology, University Hospital of Basel

49

Grants, Honors, Awards (Selection) Grants: The Department of Dermatology at UHZ awarded countless grants – primarily competitive – amounting to more than CHF 8 million in 2017/2018.

For space reasons, it is not possible to list all of them individually in this report.

Florian Anzengruber, MD – Competitive research credit, University of Zurich.

Project: “Inflammatory profile in the microenvironment of solid facial edema” – SGDV – Spirig Galderma 2018 research grant. Project “Stay phlebology” Prof. W. Salzmeier, Graz Prof. Ralph Braun, MD – Pierre Fabre Skin Cancer Research Prize 2018.

Project: “Dermatoscopy” Marie-Charlotte Brüggen, MD – SGDV - Celgene Inflammatory Skin Disease Award 2018. Project: “Acute cutaneous graft versus host disease und toxic epidermal necrolysis: from T-cells to innate lymphoid cells” Phil Cheng, PhD – Pierre Fabre Skin Cancer Research Award 2017. Project: “Uncovering novel resistance mechanisms to BRAF and MEK inhibition by integrative RNA-Seq and targeted panel sequencing” (Biobank) Prof. Reinhard Dummer, MD, together with Prof. Lukas Sommer, PhD, Institute of Anatomy, University of Zurich – CTC funding by the University of Zurich: grant for project “Investigating the functional role of cellular phenotypes in melanoma targeted therapy” in June (chosen as one of 7 top projects from 14).

Christian Greis, MD: – IUSTI Europe Certificate of Merit awarded by the International Union against Sexually Transmitted Infections, September 2017.

– 2 SSDV research awards 2018: – SGDV award, Galderma Spirig Foundation, project: “derma2go” – SGDV award, Louis Widmer, research project: “Digital Services in Dermatology” Prof. Jürg Hafner, MD – Honorary members of the Swiss Society of Dermatology and Venereology (SGDV) – Honorary member of the Société Française de Dermatologie (SFD) – Corresponding Member of the Finnish Society of

50

Dermatology – President-elect of the Swiss Society of Phlebology – Re-election to the Board of the Swiss Institute for Continuing Medical Education (SIWF) – Election as member of the EDF European Dermatology Forum, June 2018 Antonios Kolios, MD – SGDV - Eli Lilly Immunodermatology Award 2018.

Project: “Topical methotrexate-gold nanoparticles are effective in dampening the innate and adaptive immune response in an IMQ-induced psoriatic mouse model” Michael Kunz, MD – Bruno Bloch Foundation, Fellowship Travel Grant 2017 Julia-Tatjana Maul, MD – SGDV Annual Meeting 2017: Celgene Inflammatory Skin Disease Award. Project: “Efficacy and safety of systemic treatments in female patients with psoriasis – an analysis of two real-life registries” – Bruno Bloch Foundation, Fellowship Travel Grant 2018 – International Psoriasis Council Stipendium, 2018 Barbara Meier, MD, PhD – UHZ Innovation Prize 2018: ”Development of medication allergy diagnostics” Prof. Alexander Navarini, MD, PhD – Swiss Institute for Continuing Medical Education (SIWF) award for special engagement in the continuing education of physicians (September 2017) Prof. Peter Schmid-Grendelmeier, MD – Election as member of the EDF European Dermatology Forum, January 2018

16

Partners, sponsors, collaboration with industry, fundraising

With special acknowledgement to our partners Schwerpunkt “Hautkrebs” Amgen Switzerland AG Galderma SA L’Oréal/Cosmetique Active La Roche-Posay Schweiz AG Galderma Schweiz AG MSD AG Novartis Pharma Schweiz AG Pierre Fabre Suisse SA Roche Pharma (Schweiz) AG

Our ongoing efforts in medical education, public relations, marketing and networking with private practitioners are possible only thanks to external funding. We collaborate with partners in industry on post-graduate education, which gives both private practitioners and industry a platform for communication and exchange. Opportunities are also provided by our two charitable foundations, the Bruno Bloch Foundation and the Association for Skin Cancer Research (Verein für Hautkrebsforschung).

We wish to acknowledge the support of our industrial partners here. Their collaboration helps us to guarantee the quality and design of our post-graduate teaching programs. The UHZ Department of Dermatology is grateful to the sponsors and donors below for their generous support.

Schwerpunkt “Entzündliche Hautkrankheiten” AbbVie AG Celgene GmbH Eli Lilly Suisse SA Janssen-Cilag AG LEO Pharma Sarath Ltd. Novartis Pharma Schweiz AG Sanofi Genzyme Other corporate sponsors ALK Abello Allergopharma AG Almirall AG Arthrex Suisse SA AstraZeneca AG Beiersdorf AG / Eucerin Biotest AG Bristol-Myers Squibb AG CSL Behring (Schweiz) AG Gebro Pharma AG GlaxoSmithKline AG JCE Hottinger AG lBSA Institut Biochimique SA Louis Widmer AG MEDA Pharmaceuticals / Mylan Pharmaceuticals Merck (Schweiz) AG Merz Pharma (Schweiz) AG Permamed AG Pharma Medica AG Pfizer AG Sandoz Pharmaceuticals AG Shire Switzerland GmbH Sunpharma GmbH Takeda AG Ultrasun AG Zur Rose SA 51

17

Publications in 2017 and 2018

Original Papers 2017 Adamo S, Nilsson J, Krebs A, Steiner U, Cozzio A, French LE, Kolios AGA. Successful treatment of SAPHO syndrome with apremilast.

Br J Dermatol 2017 doi: 10.1111/bjd.16071 [Epub ahead of print] Amann VC, Hoffmann D, Mangana J, Dummer R, Goldinger SM. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. J Eur Acad Dermatol Venereol. 2017;31(10):1638-1640

Bousquet J, Agache I, Anto JM, Bergmann KC, Bachert C, Annesi-Maesano I, Bousquet PJ, D›Amato G, Demoly P, De Vries G, Eller E, Fokkens WJ, Fonseca J, Haahtela T, Hellings PW, Just J, Keil T, Klimek L, Kuna P, Lodrup Carlsen KC, Mösges R, Murray R, Nekam K, Onorato G, Papadopoulos NG, Samolinski B, Schmid-Grendelmeier P, Thibaudon M, Tomazic P, Triggiani M, Valiulis A, Valovirta E, Van Eerd M, Wickman M, Zuberbier T, Sheikh A. Google Trends terms reporting rhinitis and related topics differ in European countries.

Allergy. 2017;72(8):1261-1266 Braun R, Ludwig S. Hautkrebs erkennen – Le dépistage du cancer de la peau. Physio Active 2017;5:37-44 Braun RP, Ludwig S, Marghoob AA. Differential Diagnosis of Seborrheic Keratosis: Clinical and Dermoscopic Features.

J Drugs Dermatol, 2017;9:835-842 Braun RP, Mangana J, Goldinger S, French L, Dummer R, Marghoob AA. Electrical Impedance Spectroscopy in Skin Cancer Diagnosis.

Dermatol Clin. 2017;35(4):489-493

Amyere M, Revencu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour JP, Martorell L, Mazereeuw-Hautier J, Pyeritz RE, Amor DJ, Bisdorff A, Blei F, Bombei H, Dompmartin A, Brooks D, Dupont J, González-Enseñat MA, Frieden I, Gérard M, Kvarnung M, Hanson-Kahn AK, Hudgins L, Léauté-Labrèze C, McCuaig C, Metry D, Parent P, Paul C, Petit F, Phan A, Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M. Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. Circulation 2017;12;136(11):1037-1048

Braun RP, Ulrich K, Hunger R, Gaide O, Arnold A, Merat R, Dummer R, Hafner J, French LE, Cozzio A. Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right Thing?

Dermatology, 2017; 233(5):404-409

Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Häusermann P, Cozzio A, Mainetti C, Goldblum D, Läuchli S, Imhof L, Brand C, Laffitte E, Navarini AA. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017;31(11):1775-1791

Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. J Cancer Res Clin Oncol. 2017;143(10):1977-1984

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research «Melanoma Bridge», Napoli, November 30th-3rd December 2016. J Transl Med. 2017;16;15(1):236 Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017; 23;86:334-348 Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang JX, Ghosh K, Cheng PF, Lisanti S, Marchbank K, Dang V, Levesque MP, Dummer R, Xu X, Heryn M, Aplin AE, Roesch A, Caino MC, Altieri DC, Weeraratna AT. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho.

Clin Cancer Res. 2017;15;23(12):3181-3190 Blum A, Kreusch J, Stolz W, Haenssele H, Braun R, HofmannWellenhof R, Tschandl P, Zalaudek I, Kittler H. Dermoscopy for malignant and benign skin tumors: Indication and standardized terminology. Hautarzt 2017;68(8):653-673 Bossart S, Thurneysen S, Rushing E, Frontzek K, Leske H, Mihic-Probst D, Nagel HW, Mangana J, Goldinger SM, Dummer R. Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. The Oncologist 2017:22(6):749-753

52

Broekaert SM, Flux K, Kyrpychova L, Kacerovska D, Ivan D, Schön MP, Ströbel P, Michal M, Denisjuk N, Kerl K, Kazakov DV. Squared-Off Nuclei and «Appliqué» Pattern as a Histopathological Clue to Periocular Sebaceous Carcinoma: A Clinicopathological Study of 50 Neoplasms From 46 Patients. Am J Dermatopathol.

2017;39(4):275-278

Carrera C, Marchetti MA, Argenziano G, Braun RP, Halpern AC, Jaimes N, Kittler HJ, Malvehy J, Menzies SW, Pellacani G, Puig S, Rabinovitz HS, Soyer HP, Stolz W, Hofmann-Wellenhof R, Zalaudek I, Marghoob AA. Validity and Reliability of Dermoscopic Criteria Used to Differentiate Nevi from Melanoma: A Web-Based International Dermoscopy Society Study. JAMA Dermatol, 2017;7:798-806 Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;1;28(10):2581-2587 Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Rob-ert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AM. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393-403 Cusick EH, Marghoob AA, Braun RP. Laugier-Hunziker syndrome: a case of asymptomatic mucosal and acral hyperpigmentation.

Dermatol Pract Concept 2017; 7:27-30 Dissemond J, Assenheimer B, Engels P, Gerber V, Kröger K, Kurz P, Läuchli S, Probst S, Protz K, Traber J, Uttenweiler S, Strohal R. M.O.I.S.T. - ein Konzept für die Lokaltherapie chronischer Wunden.

J Dtsch Dermatol Ges. 2017;15(4):443-445

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan RJ, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart D, Moutouh de Parseval L, Demuth T, Dummer R. Phase I Dose-Escalation and Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Clin Cancer Res. 2017:15;23(18):5339-5348

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial.

Ann Oncol. 2017;1;28(6):1380-1387

Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik A, Jehl V, BozÓn V,Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology 2017;18(4):435-445

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer.

2017;86:37-45

Dziunycz PJ, Neu J, Lefort K, Djerbi N, Freiberger SN, Iotzova-Weiss G, French LE, Dotto GP, Hofbauer GF. CYFIP1 is directly controlled

by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma. PLoS One. 2017;14;12(4):e0173000

Haueis SA, Kränzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, Levesque MP, Dummer R, Goldinger SM. Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? Melanoma Res. 2017;27(3):231-237

Eggermont AMM, Dummer R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer.

2017;28;86:101-105

Iotzova-Weiss G, Freiberger SN, Johansen P, Kamarachev J, Guenova E, Dziunycz P, Roux G, Qinxiu L, Neu J, Hofbauer GFL. TLR4 as a negative regulator of keratinocyte proliferation.

PLoS One 2017 12(10):e0185668 IF 3.655

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Mat-ter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;8;376(23):2211-2222

Izar B, Sharfman W, Hodi FS, Lawrence D, Flaherty KT, Amaravadi R, Kim KB, Puzanov I, Sosman J, Dummer R, Goldinger SM, Lam L, Kakar S, Tang Z, Krieter O, McDermott DF, Atkins MB. A first-inhuman phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Cancer Med. 2017;6(8):1904-1914

Forsea AM, Tschandl P, Zalaudek I, Del Marmol V, Soyer HP, Eurodermoscopy Working Group, Argenziano G, Geller AC. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey.

J Eur Acad Dermatol Venereol. 2017;31(7):1148-1156 Freitas LF, Hamblin MR, Anzengruber F, Perussi JR, Ribeiro AO, Martins VCA, Plepis AMG. Zinc phthalocyanines attached to gold nanorods for simultaneous hyperthermic and photodynamic therapies against melanoma in vitro. J Photochem Photobiol B. 2017;30;173:181-186 Garstkiewicz M, Strittmatter G, Grossi S, Sand J, Fenin G, Werner S, French LE, Beer HD. Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression. Eur. J. Immunol. 2017;47: 806–817 Glatz M, Means T, Haas J, Steere AC, Müllegger RR. Characterization of the early local immune response to Ixodes ricinus tick bites in human skin. Exp Dermatol. 2017;26(3):263-269 Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V, Sprikkelman AB, Roberts G, Grimshaw KEC, Sigurdardottir S, Kowalski ML, Papadopoulos NG, Quirce S, Dubakiene R, Niggemann B, FernándezRivas M, Ballmer-Weber B, van Ree R, Schnadt S, Mills ENC, Keil T, Beyer K. A new framework for diagnosing food allergy in population-based research. Allergy. 2017;72(3):453-461

Jaberg-Bentele N, Kunz M, Abuhammad S, Dummer R. Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma. Case Rep Dermatol 2017: 9;9(1):65-68 Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017 Sep 19;8(1):592 Jungo P, Maul JT, Djamei V, von Felten S, Kolios AG, Czerielewski J, Yawalker N, Odermatt O, Laffitte E, Anliker M, Streit M, Augustin M, Conrad C, Hafner J, Boehncke WH, Gilliet M, Itin P, French LE, Navarini AA, Häusermann P. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology 2017;232:655-663 Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer.

2017;2;75:313-322

53

Kley C, Murer C, Maul JT, Meier B, Anzengruber F, Navarini AA. Rapid Involution of Pustules during Topical Steroid Treatment of Acute Generalized Exanthematous Pustulosis. Case Rep Dermatol. 2017; 27;9(1):135-139 Kolios AGA, Gübeli A, Meier B, Maul JT, Kündig T, Nilsson J, Hafner J, Guenova E, Kerl K, Anliker M, Kempf W, Navarini AA, French LE, Cozzio A. Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients. Dermatology 2017;233(4):268-276 Kolios AGA, Cozzio A, Zinkernagel AS, French LE, Kündig TM. Cutaneous Corynebacterium Infection Presenting with Disseminated Skin Nodules and Ulceration. Case Rep Dermatol. 2017;9:8-12 Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E*, Schoppmann SF. PD1-expression by tumor-infiltrating lymphocytes and tumor cells is associated with advanced tumor stage in patients with esophageal adenocarcinoma. Ann Surg Oncol. 2017 24(9):2698-2706 Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang YT, Lewik G, Schoppmann SF, Hoetzenecker W, Klepetko W, Guenova E, Hoetzenecker K. PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. Oncoimmunology 2017 8 6(9):e1331194 Konstantinova AM, Spagnolo DV, Stewart CJR, Kacerovska D, Shelekhova KV, Plaza JA, Suster S, Bouda J, Kyrpychova L, Michal M, Belousova IE, Kerl K, Kazakov DV. Spectrum of Changes in Anogenital Mammary-like Glands in Primary Extramammary (Anogenital) Paget Disease and Their Possible Role in the Pathogenesis of the Disease.

Am J Surg Pathol. 2017;41(8):1053-1058 Kostner L, Anzengruber F, Guillod C, Recher M, Schmid-Grendelmeier P, Navarini AA. Allergic Contact Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):141-152 Kuhn-Régnier S, Mangana J, Kerl K, Kamarachev J, French LE, Cozzio A, Navarini AA. A Report of Two Cases of Solid Facial Edema in Acne.

Dermatol Ther (Heidelb). 2017;7(1):167-174 Kukutsch NA, Argenziano G, Bergmann W, Braun RP. The opinion of dermoscopy experts about teledermoscopy involving primary care physicians and dermatologists. J Eur Acad Deramtol Venereol, 2017;31(10):e470-e471 Lemaire M, Oppliger A, Hotz P, Renauld JC, Braun J, Maggi M, Barresi F, Schmid-Grendelmeier P, Huaux F, Dressel H. Can serum cytokine profile discriminate irritant-induced and allergen-induced symptoms? A cross-sectional study in workers mostly exposed to laboratory animals. Occup Environ Med. 2017;74(8):592-600 Leong C, Buttafuoco A, Glatz M, Bosshard PP. Antifungal Susceptibility Testing of Malassezia spp. with an Optimized Colorimetric Broth Microdilution Method. J Clin Microbiol. 2017;55(6):1883-1893 Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;9;377(19):1813-1823 Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncol. 2017;1;3(11):1511-1519.

54

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res. 2017;27(4):358-368 Mangana J, Guenova E, Kerl K, Urosevic-Maiwald M, Amann VC, Bayard C, Dummer R, French LE. Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). Case Rep Dermatol.

2017;21;9(1):74-79 Mangold AR, Thompson A, Davis MD, Saulite I, Cozzio A, Guenova E, Hodak E, Amitay-Laish I, Pujol RM, Pittelkow MR, Gniadecki R. Early clinical manifestations of Sézary syndrome: A Multicenter Retrospective Cohort Study. J Am Acad Dermatol 2017 77(4):719-727 Maul JT, Djamei V, Kolios AG, Meier B, Czernielewski J, Jungo P, Yawalker N, Mainetti C, Laffitte E, Spehr C, Anliker M, Streit M, Augustin M, Rustenbach S, Conrad C, Hafner J, Boehncke WH, Borradori L, Gilliet M, Itin P, French LE, Häusermann P, Navarini AA. Efficacy and Survival of Systemic Psoriasis Treatment: An Analysis of the Swiss Registry SDNTT. Dermatology 2017;232:640-647 Maul JT, Maier PW, Anzengruber F, Murer C, Bosshard PP, Kerl K, French LE, Navarini AA. A case of tinea incognita and differential diagnosis of figurate erythema. Med Mycol Case Rep. 2017;3:18:8-11 Markun S, Scherz N, Rosemann T, Tandjung R. Braun RP. Mobile teledermatology for skin cancer screening: A diagnostic accuracy study.

Medicine (Baltimore) 2017;96(10) Minini R, Rohrmann S, Braun R, Korol D, Dehler S. Incidence trends and clinical-pathological characteristics of cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland. Melanoma Res. 2017;2:145-151 Mitteldorf C, Berisha A, Pfaltz MC, Broekaert SMC, Schön MP, Kerl K, Kempf W. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. Am J Surg Pathol. 2017;41(7):998-1004 Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW. Pillars Article: Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. Science. 1997. 275: 540-543.

J Immunol. 2017;199:3717-3720 Muggli D, Maul JT,Anzengruber F, Fopp MW, Navarini AA. Secukinumab for Acrodermatitis Continua of Hallopeau.JAMA Dermatol.

2017;1;153(4):336-337 Murer C, Kränzlin-Stieger P, French LE, Dummer R, Goldinger SM. Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.

Melanoma Res. 2017;27(4):396-39 Nägeli M, Imhof L, Läuchli S. Welche Tumoren schneiden, welche lokal behandeln, welche bestrahlen? Dermatologie Praxis 2017; Vol. 27 Nr. 2 Neu J, Dziunycz PJ, Dzung A, Lefort K, Falke M, Denzler R, Freiberger SN, Iotzova-Weiss G, Kuzmanov A, Levesque MP, Dotto GP, Hofbauer GFL. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. PLoS One 2017;20;12(9)

Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TD, Levesque M, Dummer R, Hamid O, Daud A. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.

Br J Cancer 2017:25;116(9):1141-1147 Oppliger A, Barresi F, Maggi M, Schmid-Grendelmeier P, Huaux F, Hotz P, Dressel H. Association of Endotoxin and Allergens with Respiratory and Skin Symptoms: A Descriptive Study in Laboratory Animal Workers. Ann Work Expo Health. 2017;1;61(7):822-835 Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet.

2017;1;390(10089):40-49 Prince MH, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, L Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel T, Wang Y, PalancaWessels MC, E Zagadailov, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M on behalf of the ALCANZA study group. Brentuximab vedotin or physician’s choice in CD30positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet 2017:5;390(10094):555-566 Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L. low neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Nat Commun. 2017 Dec 7;8(1):1988 Reich K, Pinter A, Lacour JP, Ferrandiz C, Mical G, French LE, Lomaga M, Dutronc Y, Henneges C, Wilhelm S, Hartz S, Paul C; IXORA-S investigators. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a Phase 3 study. Br J Dermatol 2017;4:1014-1023 Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;7;170(6):1109-1119 Rodriguez-Perez N, Schiavi E, Frei R, Ferstl R, Wawrzyniak P, Smolinska S, Sokolowska M, Sievi NA, Kohler M, Schmid-Grendelmeier P, Michalovich D, Simpson KD, Hessel EM, Jutel M, Martin-Fontecha M, Palomares O, Akdis CA, O’Mahony L. Altered fatty acid metabolism and reduced stearoyl-coenzyme a desaturase activity in asthma.

Allergy. 2017;72(11):1744-1752

Schaefer SM, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, Dummer R, Nicolis SK, Sommer L. Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene.

2017;36(31):4516-4524 Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, Stadler R. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2017;31(11):1841-1847 Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebocontrolled, phase 3 efficacy trial. Lancet Infect Dis. 2017;17:322-329 Silverberg JI, Thyssen JP, Paller AS, Drucker AM, Wollenberg A, Lee KH, Kabashima K, Todd G, Schmid-Grendelmeier P, Bieber T. What’s in a name? Atopic dermatitis or atopic eczema, but not eczema alone. Allergy. 2017;72(12):2026-2030 Sinz C, Tschandl P, Rosendahl C, Akay BN, Argenziano G, Blum A, Braun RP, Cabo H, Gourhant JY, Kreusch J, Lallas A. Lapins J, Marghoob AA, Menzies SW, Paoli J, Rabinovitz HS, Rinner C, Scope A, Soyer HP, Thomas L, Zalaudek I, Kittler H. Accuracy of dermatoscopy for the diagnosis of nonpigmented cancers of the skin.

J Am Acad Dermatol 2017, 6:1100-1109 Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017;9(8):1011-1029 Strohal R, Assenheimer B, Augustin M, Hämmerle G, Läuchli S, Pundt B, Stern G, Storck M, Ulrich C. Wound management with enzyme alginogels : Expert consensus. Hautarzt. 2017;68(1):36-42 Surber Ch, Braun RP. Sonnenschutz Swiss Medical Forum, 2017;25:544-555 Theiler M, Baselga E, Gerth-Kahlert C, Mathes EF, Schwieger-Briel A, Chaloupka K, Weibel L, Frieden IJ. Infantile hemangiomas with conjunctival involvement: An underreported occurrence. Pediatr Dermatol. 2017;34(6):681-685 Theiler M, Neuhaus K, Kerl K, Weibel L. The spectrum of skin biopsies and excisions in a pediatric skin center. Eur J Pediatr.

2017;176(12):1663-1668

Saulite I, Pilmane M, Guenova E, Kisis J. Expression of inflammatory cytokines in psoriatic nails. J Eur Acad Dermatol Venereol. 2017 31(4):e210-e212

Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Ba-nayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417-424

Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80-91

Treudler R, Franke A, Schmiedeknecht A, Ballmer-Weber B, Worm M, Werfel T, Jappe U, Biedermann T, Schmitt J, Brehler R, Kleinheinz A, Kleine-Tebbe J, Brüning H, Ruëff F, Ring J, Saloga J, Schäkel K, Holzhauser T, Vieths S, Simon Jan C. BASALIT-trial: Double blind placebo controlled allergen immunotherapy with rBet v 1-FV in birch related soy allergy. Allergy 2017;72:1243-1253

Roider E, Signer C, Fehrenbacher B, Metzler G, Schaller M, Kamarachev J, Kerl K, Balabanov S, Jochum W, Hoetzenecker W, Cozzio A, French LE, Dummer R, Guenova E. Individualized Treatment Approaches for Langerhans Cell Histiocytosis. Br J Dermatol. 2017 doi: 10.1111/bjd.16171 [Epub ahead of print]

55

Uter W, Amario-Hita JC, Balato A, Ballmer-Weber B, Bauer A, Belloni Fortina A, Bircher A, Chowdhury MMU, Cooper SM, CzarneckaOperacz M, Dugonik A, Gallo R, Giménez-Arnau A, Johansen JD, John SM, Kieć-Świerczyńska M, Kmecl T, Kręcisz B, Larese Filon F, Mahler V, Pesonen M, Rustemeyer T, Sadowska-Przytocka A, Sánchez-Pérez J, Schliemann S, Schuttelaar ML, Simon D, Spiewak R, Valiukevičienė S, Weisshaar E, White IR, Wilkinson SM. European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14. J Eur Acad Dermatol Venereol 2017; 31(9):1516-1525 Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, Klink R; GAP investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol.

2017;pii: S0091-6749(17)31088-6 van Hage M, Schmid-Grendelmeier P, Skevaki C, Plebani M, Canonica W, Kleine-Tebbe J, Nystrand M, Jafari-Mamaghani M, Jakob T. Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study. Clin Chem Lab Med. 2017;1;55(4):571-577 Wangorsch A, Jamin A, Lidholm J, Gräni N, Lang C, Ballmer-Weber B, Vieths S, Scheurer S. Identification and implication of an allergenic PR-10 protein from walnut in birch pollen associated walnut allergy. Mol Nutr Food Res 2017;61(4) Weber B, Bachmann CC, Braun R, Abraham AG, Serra AL, Hofbauer GFL. 25-Hydroxivitamn-D3 serum modulation after use of sunbeds compliant with European Union standards: A randomized open observational trial. J Am Acad Dermatol 2017;1:48-54 Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;5;377(14):1345-1356 Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hem-mings BA, Wicki A. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. 2017;25;8(41):69204-69218 Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF. Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation. Immunology 2017 150:329-342 Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017; 16;75:47-55 Zulehner N, Nagl B, Briza P, Roulias A, Ballmer-Weber B; Zlabinger G, Ferreira F, Bohle B. Dau c 1, the Bet v 1 homolog in carrot, shows sensitizing activity, evidence at the T-cell level. Allergy.

2017;72(2):244-251

56

Reviews 2017 Bachmann, M. F.; Kundig, T. M. Allergen-specific immunotherapy: is it vaccination against toxins after all? Allergy. 2017;72(1):13-23 Ballmer-Weber BK, Helbling A. Allergische Rhinitis, eine Volkserkrankung des 20. Jahrhunderts. Swiss Medical Forum; 2017;17:179-186 Ballmer-Weber BK, Beyer K. Food challenges. J Allergy Clin Immunol.

2017 Jul 27. pii: S0091-6749(17)31196-X. doi: 10.1016/j.jaci.2017.06.038.

[Epub ahead of print] Bieber T, D’Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, Schmid-Grendelmeier P. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4S):S58-S64 Binkert A, Dummer R. Dermatoonkologie – was kann in der Hausarztpraxis angeboten werden? Praxis 2017;106(9)471-475 Bosshard PP. Dermatophytosen - Update zu Klinik, Epidemiologie und Diagnose. Dermatologie Praxis 2017;1:10-15 Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, RobaloCordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PAM, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicioğlu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JOB, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Khaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N’Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LTT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GMY, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, NamazovaBaranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O’Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman

Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FER, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy. 2017 Feb 20;7:5 Bousquet J, Bewick M, Cano A, Eklund P, Fico G, Goswami N, Guldemond NA, Henderson D, Hinkema MJ, Liotta G, Mair A, Molloy W, Monaco A, Monsonis-Paya I, Nizinska A, Papadopoulos H, Pavlickova A, Pecorelli S, Prados-Torres A, Roller-Wirnsberger RE, Somekh D, VeraMuñoz C, Visser F, Farrell J, Malva J, Andersen Ranberg K, Camuzat T, Carriazo AM, Crooks G, Gutter Z, Iaccarino G, Manuel de Keenoy E, Moda G, Rodriguez-Mañas L, Vontetsianos T, Abreu C, Alonso J, Alonso-Bouzon C, Ankri J, Arredondo MT, Avolio F, Bedbrook A, Białoszewski AZ, Blain H, Bourret R, Cabrera-Umpierrez MF, Catala A, O’Caoimh R, Cesari M, Chavannes NH, Correia-da-Sousa J, Dedeu T, Ferrando M, Ferri M, Fokkens WJ, Garcia-Lizana F, Guérin O, Hellings PW, Haahtela T, Illario M, Inzerilli MC, Lodrup Carlsen KC, Kardas P, Keil T, Maggio M, Mendez-Zorrilla A, Menditto E, Mercier J, Michel JP, Murray R, Nogues M, O’Byrne-Maguire I, Pappa D, Parent AS, Pastorino M, Robalo-Cordeiro C, Samolinski B, Siciliano P, Teixeira AM, Tsartara SI, Valiulis A, Vandenplas O, Vasankari T, Vellas B, Vollenbroek-Hutten M, Wickman M, Yorgancioglu A, Zuberbier T, Barbagallo M, Canonica GW, Klimek L, Maggi S, Aberer W, Akdis C, Adcock IM, Agache I, Albera C, Alonso-Trujillo F, Angel Guarcia M, Annesi-Maesano I, Apostolo J, Arshad SH, Attalin V, Avignon A, Bachert C, Baroni I, Bel E, Benson M, Bescos C, Blasi F, Barbara C, Bergmann KC, Bernard PL, Bonini S, Bousquet PJ, Branchini B, Brightling CE, Bruguière V, Bunu C, Bush A, Caimmi DP, Calderon MA, Canovas G, Cardona V, Carlsen KH, Cesario A, Chkhartishvili E, Chiron R, Chivato T, Chung KF, d’Angelantonio M, De Carlo G, Cholley D, Chorin F, Combe B, Compas B, Costa DJ, Costa E, Coste O, Coupet AL, Crepaldi G, Custovic A, Dahl R, Dahlen SE, Demoly P, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Du Toit G, Dubakiene R, Dupeyron A, Emuzyte R, Fiocchi A, Wagner A, Fletcher M, Fonseca J, Fougère B, Gamkrelidze A, Garces G, Garcia-Aymeric J, Garcia-Zapirain B, Gemicioğlu B, Gouder C, Hellquist-Dahl B, Hermosilla-Gimeno I, Héve D, Holland C, Humbert M, Hyland M, Johnston SL, Just J, Jutel M, Kaidashev IP, Khaitov M, Kalayci O, Kalyoncu AF, Keijser W, Kerstjens H, Knezović J, Kowalski M, Koppelman GH, Kotska T, Kovac M, Kull I, Kuna P, Kvedariene V, Lepore V, MacNee W, Maggio M, Magnan A, Majer I, Manning P, Marcucci M, Marti T, Masoli M, Melen E, Miculinic N, Mihaltan F, Milenkovic B, Millot-Keurinck J, Mlinarić H, Momas I, Montefort S, Morais-Almeida M, Moreno-Casbas T, Mösges R, Mullol J, Nadif R, Nalin M, NavarroPardo E, Nekam K, Ninot G, Paccard D, Pais S, Palummeri E, Panzner P, Papadopoulos NK, Papanikolaou C, Passalacqua G, Pastor E, Perrot M, Plavec D, Popov TA, Postma DS, Price D, Raffort N, Reuzeau JC, Robine JM, Rodenas F, Robusto F, Roche N, Romano A, Romano V, Rosado-Pinto J, Roubille F, Ruiz F, Ryan D, Salcedo T, SchmidGrendelmeier P, Schulz H, Schunemann HJ, Serrano E, Sheikh A, Shields M, Siafakas N, Scichilone N, Siciliano P, Skrindo I, Smit HA, Sourdet S, Sousa-Costa E, Spranger O, Sooronbaev T, Sruk V, Sterk PJ, Todo-Bom A, Touchon J, Tramontano D, Triggiani M, Tsartara SI, Valero AL, Valovirta E, van Ganse E, van Hage M, van den Berge M, Vandenplas O, Ventura MT, Vergara I, Vezzani G, Vidal D, Viegi G, Wagemann M, Whalley B, Wickman M, Wilson N, Yiallouros PK, Žagar M, Zaidi A, Zidarn M, Hoogerwerf EJ, Usero J, Zuffada R, Senn A, de

Oliveira-Alves B. Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA. J Nutr Health Aging.

2017;21(1):92-104 Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, BosnicAnticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O›Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958 Dummer R, Hoeller Chr, Pezzani Gruter I, Michielin O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol Immunother 2017; 66:683-695 Dummer R, Ludwig S, Kaufmann C, Binkert A, Mangana J, Goldinger S, Braun RP. Modernes Management von Hauttumoren.

Swiss Medical Forum 2017;17(33):678-685 Dummer R, Ramelyte E, Levesque M, Goldinger SM, Braun R. Critical aspects to achieve a high-quality melanoma clinic. Curr Opin Oncol 2017; 29:145-150 Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque M, Kölblinger P. MEK inhibition and immune responses in advanced melanoma. Oncoimmunology 2017:10;6(8) Glatz M, Bosshard P, Schmid-Grendelmeier P. The Role of Fungi in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):63-74 Glatz M, Müllegger RR. Cutaneous manifestations of Lyme disease: Pitfalls in the serological diagnostic workup. Hautarzt.

2017;68(4):329-339 Greis C., Lautenschlager S. Flagellate-Dermatitis: Peitschenhiebartige Läsionen. Praxis (Bern 1994). 2017;106(14):795-796 Greis C., Terrani I., Lautenschlager S. Das SAPHO-Syndrom: Synovitis, Akne, Pustulosis, Hyperostose, Osteitis – Ein Fallbeispiel aus dem klinischen Alltag. Dermatologica Helvetica 2017;29(1):30-33 Greis C., Rasuly Z., Liebregts T. Intestinal T cell homing is associated with gastric emptying and epithelial barrier function in critically ill: A prospective observational study. Critical Care 2017;21(1):70 Harrington K, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger A, Dummer R. A practical guide to the handling and administration of talimogene laherparepvec in Europe. OncoTargets and Therapy 2017;10:3867-3880 Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T, Agache I, Bernal-Sprekelsen M, Canonica GW, Gevaert P, Joos G, Lund V, Muraro A, Onerci M, Zuberbier T, Pugin B, Seys SF, Bousquet J; ARIA and EPOS working groups. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement.

Allergy. 2017;72(9):1297-1305

57

Hunger RE, Laffitte E, Läuchli S, Mainetti C, Mühlstädt M, Schiller P, Lapointe AK, Meschberger P, Navarini AA. Swiss Practice Recommendations for the Management of Hidradenitis Suppurati-va/ Acne Inversa. Dermatology 2017;233(2-3):113-119 Ishida Y, Otsuka A, Tanaka H, Levesque MP, Dummer R, Kabashima K. HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients. J Invest Dermatol. 2017;137(11):2443-2444 Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, Germenis AE, Grumach AS, Luczay A, Varga L, Zanichelli A; HAWK. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300-313 Frauchiger AL, Brüggen MC, Goldinger SM, Dummer R. Interstitial granulomatous dermatitis during talimogen laherparepvec treatment. Melanoma Res. 2017;27(4):400-401 Klimek L, Pfaar O, Bousquet J, Senti G, Kündig T. Allergen immunotherapy in allergic rhinitis: current use and future trends.

Expert Rev Clin Immunol. 2017;13:897-906 Kresbach H, Guenova E. Lymphome. Das Sézary Syndrom.

Dermatologie Praxis. 2017 27(5):2-6 Koelblinger P, Dornbierer J, Dummer R. A review of binimetinib for the treatment of mutant cutaneous melanoma. Future Oncol.

2017;13(20):1755-1766

Reese I, Ballmer-Weber B, Beyer K, Fuchs T, Kleine-Tebbe J, Klimek L, Lepp U, Niggemann B, Saloga J, Schäfer C, Werfel T, Zuberbier T, Worm M. German guideline for the management of adverse reactions to ingested histamine: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA) and the Swiss Society for Allergology and Immunology (SGAI). Allergo J Int. 2017;26(2):72-79 Saulite I, Guenova E, Hoetzenecker W. Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

Curr Probl Dermatol. 2018;53:70-81 Singer J, Ruscheweyh HJ, Hofmann AL, Thurnherr T, Singer F, Toussaint NC, Ng CKY, Piscuoglio S, Beisel C, Christofori G, Dummer R, Hall MN, Krek W, Levesque M, Manz MG, Moch H, Papassotiropoulos A, Stekhoven DJ, Wild P, Wüst T, Rinn B, Beerenwinkel N. NGS-pipe: a flexible, easily extendable, and highly configurable framework for NGS analysis. Bioinformatics. 2017 Aug 28. doi: 10.1093/bioinformatics/btx540 [Epub ahead of print] Spertini F, Ballmer-Weber BK, Bircher A, Ferrari G, Grabbe J, Hausmann O, Helbling A, Hoetzenecker W, Jörg L, Di Lucca J, Scherer-Hofmeier K, Seebach J, Simon D, Spoerl D, Yawalkar N, Schmid-Grendelmeier P. Urticariamanagement in der Grundversorgung. Swiss Medical Forum 2017; 17: 660-664

Koelblinger P, Dummer R. Targeted treatment of advanced NRAS-mutated melanoma. Oncotarget 2017;29;8(49):84616-84617

Theiler M, Schwieger-Briel A, Weibel L. Acute skin infections and their imitators in children : A photo quiz. Hautarzt.

2017;68(10):774-783

Kündig, T. Research at the Department of Dermatology, USZToday - Focus on Immuno- and Targeted Therapies in Dermatooncology and Severe Inflammatory Skin Diseases.

Aktuelle Dermatologie 2017;43:301-304

Theiler M, Oza VS, Mathes EF, Dvorak CC, McCalmont TH, Yeh I, Sidbury R, Cordoro KM. Eosinophilic Pustular Folliculitis in Children after Stem Cell Transplantation: An Eruption Distinct from GraftVersus-Host Disease.Pediatr Dermatol. 2017;34(3):326-330

Levesque MP, Cheng PF, Raaijmakers M, Saltari A, Dummer R. Metastatic melanoma moves on: translational science in the era of personalized medicine. Cancer Metastasis Rev 2017:36(1):7-21

Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke CD, Ortiz-Romero P, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer M, Whittaker S, Willemze R, Knobler R. European Organisation for Research and Treatment of Cancer consensus recommendation for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer 2017;30;77:57-74

Ludwig S, Mangana J, Dummer R, Kamarashev J, Hafner J, Braun RP. Der Naevus. Swiss Medical Forum 2017;17(37):784-789 Nonomura Y, Otsuka A, Ohtsuka M, Yamamoto T, Dummer R, Kabashima K. ADAMTSL5 is up-regulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab.

J Eur Acad Dermatol Venereol. 2017;31(2):e100-e101 Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Gold-man J, La Grenada L, Pirmohamed M, Shear NH, Tassaeeyakul W, Hoetzenecker W, Klaewsongkram J, Rerkpattanapipat T, Manuyakorn W, Yasuda SU, Sharon VR, Sukhov A, Micheletti R, Stuerung J, French LE, Cheng MY. Stevens-Johnson Syndrom and Toxic Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group.

JAMA Dermatmol, 2017;153:587-592 Ramelyte E, Bylaite-Bucinskiene M, Dummer R, Imhof L. Successful Use of Grenz Rays for Disseminated Superficial Actinic Porokeratosis: Report of 8 Cases. Dermatology. 2017;233(2-3):217-222 Ramelyte E, Koelblinger P, Dummer R. Oestrogen receptor expression in melanoma. J Eur Acad Dermatol Venereol.

2017;31(9):1399-1400 Rebsamen U, Guenova E, Vallelian F. CME. Erythema nodosum.

Praxis (Bern 1994). 2017 106(18):973-979

58

Urosevic-Maiwald M, Mangana J, Dummer R. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Ann Oncol.

2017:1;28(7):1673-1675 Yazdi AS, Barlin M, Böhm K, Gendrisch F, Ghorbanalipoor S, Häberle S, Hamel A, Hüning S, Hüttner C, Iwanova I, Kanaki T, Kimeswenger S, Lohmann N, Munir S, Muzumdar S, Pereira MP, Peking P, Plesser K, Rendon A, Rentschler M, Schlumprecht C, Smorodchenko A, Stock M, Till-manns J, Uslu U, Ghoreschi K, Glatz M, Grabbe S, Kunz M, Ludwig R, Scharffetter-Kochanek K, Loser K. ADF Winter School – An exciting concept of the Arbeitsgemeinschaft Dermatologische Forschung to connect young scientists and clinician scientists in Dermatology at the top of Germany. Exp Dermatol. 2017;26(3):292-294 Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, Ferrer M, Knulst A, Giménez-Arnau A. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol 2017;27(1):10-19

Book Chapters 2017 Dummer Ong PY and Schmid-Grendelmeier. Allergic Skin Diseases.

An Issue of Immunology and Allergy Clinic of North America.

Elsevier 2017, ISBN: 978-0-323-49651-3

Original Papers 2018 Anzengruber F, Alotaibi F, Kaufmann LS, Ghosh A, Oswald MR, Maul JT, Meier B, French LE, Bonmarin M, Navarini AA. Thermography: High sensitivity and specificity diagnosing contact dermatitis in patch testing. Allergol Int. 2018 Dec 28. pii: S1323-8930(18)30163-1. doi: 10.1016/j.alit.2018.12.001. [Epub ahead of print] Anzengruber F, Drach M, Maul JT, Kolios AG, Meier B, Navarini AA. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.

J Eur Acad Dermatol Venereol. 2018;32(7):e274-e276 Anzengruber F, Ghosh A, Maul JT, Drach M, Navarini AA. Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis. Psoriasis (Auckl). 2018:23;8:7-11 Anzengruber F, Mergenthaler C, Murer C, Dummer R. Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study. Dermatology 2018;21:1-7 Anzengruber F, Ruhwinkel K, Ghosh A, Klaghofer R, Lang UE, Navarini AA. Wide range of age of onset and low referral rates to psychiatry in a large cohort of acne excoriée at a Swiss tertiary hospital. J Dermatolog Treat. 2018;(3):277-280.

Birnbaum JH, Wanner D, Gietl AF, Saake A, Kündig TM, Hock C, Nitsch RM, Tackenberg C. Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer›s disease patients. Stem Cell Res. 2018;27:121-130 Brinker TJ, Hekler A, von Kalle C, Schadendorf D, Esser S, Berking C, Zacher MT, Sondermann W, Grabe N, Steeb T, Utikal JS, French LE, Enk AH. Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. J Med Internet Res 2018:24;20(10):e11871

Clocchiatti A, Ghosh S, Procopio MG, Mazzeo L, Bordignon P, Ostano P, Goruppi S, Bottoni G, Katarkar A, Levesque M, Kölblinger P, Dummer R, Neel V, Özdemir BC, Dotto GP. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. J Clin Invest. 2018:3;128(12):5531-5548 Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, Lapointe AK, French LE, Vernez M, Gilliet M. TNF Blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018:2;9(1):25 Contassot E, French LE. Propionibacterium acnes Strains Differentially Regulate the Fate of Th17 Responses in the Skin. J Invest Dermatol 2018;138:251-253 Chou CF, Hsieh YH, Grubbs CJ, Atigadda VR, Mobley JA, Dummer R, Muccio DD, Eto I, Elmets CA, Garvey WT, Chang PL. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci. 2018;90(3):343-356 da Cunha KC, Riat A, Normand A-C et al. Fast identification of dermatophytes by MALDI-TOF/MS using direct transfer of fungal cells on ground steel target plates. Mycoses 2018:doi: 10.1111/myc.12793 Datema MR, van Ree R, Asero R, Barreales L, Belohlavkova S, de Blay F, Clausen M, Dubakiene R, Fernández-Perez C, Fritsche P, Gislason D, Hoffmann-Sommergruber K, Jedrzejczak-Czechowicz M, Jongejan L, Knulst AC, Kowalski M, Kralimarkova TZ, Le TM, Lidholm J, Papadopoulos NG, Popov TA, Del Prado N, Purohit A, Reig I, Seneviratne SL, Sinaniotis A, Versteeg SA, Vieths S, Zwinderman AH, Mills ENC, Fernández-Rivas M, Ballmer-Weber B. CRD and beyond: multivariable regression models to predict severity of hazelnut allergy.

Allergy 2018;73:549–55 Deubelbeiss C, Kolios AGA, Anzengruber F, French LE, Yawalkar N, Kempf W, Kerl K, Meier B, Navarini AA. TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists. J Cutan Pathol. 2018;45(1):23-28 Dimitriou F, Braun RP, Mangana J. Update on adjuvant melanoma therapy. Curr Opin Oncol. 2018;30(2):118-124 Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger SM, Barysch M, Franzen D, Kamarachev J, Braun R, Dummer R, Mangana J. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018;28(3):230-236

Brüggen MC, Kerl K, Haralambieva E, Schanz U, Chang YT, Ignatova D, Dummer R, Cozzio A, Hoetzenecker W, French LE, Guenova E. Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study. Acta Derm Venereol.

2018:10;98(9):835-841

Dimitriou F, Krattinger R, Ramelyte E, Barysch MJ, Micaletto S, Dummer R, Goldinger SM. The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Curr Oncol Rep. 2018:24;20(11):87

Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R. Methadone – not a magic bullet in melanoma therapy. Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R. Methadone-Not a magic bullet in melanoma therapy. Exp Dermatol. 2018;27(6):694-696

Dimitriou F, Mangana J, Micaletto S, Braun RP, Dummer R. Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma. Melanoma Res. 2019;29(1):107-108

Cazzaniga S, Apfelbacher C, Diepgen T, Ofenloch RF, Weisshaar E, Molin S, Bauer A, Mahler V, Elsner P, Schmitt J, Ballmer-Weber BK, Spring P, Naldi L, Borradori L, Simon D. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data.

Br J Dermatol. 2018;178(1):229-237

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R. “Cytokine Release Syndrome during Sequential Treatment with Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma“. J Immunother. 2018:1:29-32

Cazzaniga S, Ballmer-Weber BK, Gräni N, Spring P, Bircher A, Anliker M, Sonntag AK, Piletta P, Huber C, Diepgen TL, Apfelbacher C, Naldi L, Borradori L, Simon D. Chronic hand eczema: A prospective analysis of the Swiss CARPE registry focusing on factors associated with clinical and quality of life improvement. Contact Dermatitis.

2018;79(3):136-148

Dissemond J, Eder S, Läuchli S, Partsch H, Stücker M, Vanscheidt W. Compression therapy of venous leg ulcers in the decongestion phase. Med Klin Intensivmed Notfmed. 2018;113(7):552-559

59

Doerschner M, Pekar-Lukacs A, Messerli-Odermatt O, DommannScherrer C, Rütti M, Müller AM, Nair G, Kamarachev J, Kerl K, Beer M, Messerli M, Frauenknecht K, Haralambieva E, Hoetzenecker W, French LE, Guenova E. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Br J Dermatol. 2018 Dec 18. doi: 10.1111/bjd.17535. [Epub ahead of print] Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-615 Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.

2018 Oct;19(10):1315-1327 Dummer R, Michielin O, Nägeli MC, M Goldinger S, Campigotto F, Kriemler-Krahn U, Schmid H, Pedroncelli A, Micaletto S, Schadendorf D. Phase I, open-label study of pasireotide in patients with BRAFwild type and NRAS-wild type, unresectable and/or metastatic melanoma. ESMO Open. 2018:23;3(5):e000388 Farzanfar D, Dowlati Y, French LE, Lowes MA, Alavi A. Inflammation: A Contributor to Depressive Comorbidity in Inflammation Skin Disease. Skin Pharmacol Physiol, 2018;5:246-251 Fenini G, Grossi S, Contassot E, Biedermann T, Reichmann E, French LE, Beer HD. Genome editing of human primary keratinocytes by CRISPR/Cas9 reveals an essential role of the NLRP1 inflammasome in UVB sensing. J Invest Dermatol. 2018;12:2644-2652 Fenini G, Grossi S, Gehrke S, Beer HD, Satoh TK, Contassot E, French LE. The p38 Mitogen-Activated Protein Kinase Critically Regulates Human Keratinocyte Inflammasome Activation. J Invest Dermatol.

2018;138(6):1380-1390 Fettelschoss-Gabriel A, Fettelschoss V, Olomski F, Birkmann K, Thoms F, Bühler M, Kummer M, Zeltins A, Kündig TM, Bachmann MF. Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses. Allergy. 2018 Nov 7. doi: 10.1111/ all.13659. [Epub ahead of print] Fettelschoss-Gabriel A, Fettelschoss V, Thoms F, Giese C, Daniel M, Olomski F, Kamarachev J, Birkmann K, Bühler M, Kummer M, Zeltins A, Marti E, Kündig TM, Bachmann MF. Treating insect-bite hypersensitivity in horses with active vaccination against IL-5. J Allergy Clin Immunol. 2018:142(4):1194-1205 Franzen D, Schad K, Kowalski B, Clarenbach CF, Stupp R, Dummer R, Kohler M. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study.

Cancer Immunol Immunother 2018 Jan;67(1):127-134 Freiberger SN, Leuthard DS, Duda A, Contassot E, Thallmair M, Kündig TM, Johansen P. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice. Eur J Pharm Sci. 2018;115:362-368

60

Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nägeli M, Mangana J, Müllhaupt B, Jenni F, Misselwitz B. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research. Transplant Direct. 2018 Jul 20;4(8):e376 Geller S, Marghoob AA, Scope A, Braun RP, Myskowski PL. Dermoscopy and the diagnosis of primary cutaneous B-cell lymphoma.

J Eur Acad Dermatol Venereol.2018;32(1):53-56 Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

J Eur Acad Dermatol Venereol. 2018;Nov 23. doi: 10.1111/jdv.15363 [Epub ahead of print] Greis C, Meier Zürcher C, Djamei V, Moser A, Lautenschlager S, Navarini AA. Unmet digital health service needs in dermatology patients. J Dermatolog Treat. 2018;29(7):643-647 Grillová L, Bawa T, Mikalová L et al. Molecular characterization of Treponema pallidum subsp. pallidum in Switzerland and France with a new multilocus sequence typing scheme. PLoS One. 2018;13(7) Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer.2018;91:168-170 Häfliger EM, Ramelyte E, Mangana J, Kunz M, Kazakov DV, Dummer R, Cheng PF. Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. Melanoma Res. 2018;28(5):442-450 Haenssle HA, Fink C, Schneiderbauer R, Toberer F, Buhl T, Blum A, Kalloo A, Hassan ABH, Thomas L, Enk A, Uhlmann L; Reader study level-I and level-II Groups. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists.

Ann Oncol. 2018 Aug 1;29(8):1836-1842 Hanfstingl K, Pekar-Lukacs A, Motz R, Guenova E, Hoetzenecker W. Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab.

Case Rep Dermatol. 2018;10, 97-100 Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219. [Epub ahead of print] Hartwig T, Zwicky P, Schreiner B, Yawalkar N, Cheng P, Navarini A, Dummer R, Flatz L, Conrad C, Schlapbach C, Becher B. Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.

Cell Rep. 2018:26;25(13):3564-3572.e4 Hiebert P, Wietecha MS, Cangkrama M, Haertel E, Mavrogonatou E, Stumpe M, Steenbock H, Grossi S, Beer HD, Angel P, Brinckmann J, Kletsas D, Dengjel J, Werner S. Nrf2-Mediated Fibroblast Reprogramming Drives Cellular Senescence by Targeting the Matrisome.

Dev Cell. 2018:16;46(2):145-161.e10

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1480–92 Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MM, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res. 2019;7(1):77-85 Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018:30;104:201-209 Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204 Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. European Journal of Cancer 2018;98:10-16 Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH. Tofacitinib for the Treatment of Pyoderma Gangrenosum. Clin Gastroenterol Hepatol. 2018 Nov 4. pii: S1542-3565(18)31214-X. doi: 10.1016/j.cgh.2018.10.047. [Epub ahead of print] Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology, 2018:13;7(6):e1435226

Krähenbühl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez L, Horak C, Levesque M, Dummer R, Cheng PF. A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia 2018;20(2):218-225 Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018;24(2):144-153 Kunz M, Braun RP, Mangana J. Basal Cell Carcinoma Mimicking Desmoplastic Trichoepithelioma: A Case with Correlation of Dermoscopy and Histology. Case Rep Dermatol, 2018;2:118-124 Kunz M, Kerl K, Braun R. Basal Cell Carcinoma Mimicking Desmoplastic Trichoepithelioma: A Case with Correlation of Dermoscopy and Histology. Case Rep Dermatol 2018;10:133-137 Kunz M, Svensson H, Paoli J. Dermoscopic rainbow pattern: A clue to diagnosing aneurysmal atypical fibroxanthoma. JAAD Case Reports. 2018;4(4):292-294 Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol.2018;32(3):372-381 Leuthard DS, Duda A, Freiberger SN, Weiss S, Dommann I, Fenini G, Contassot E, Kramer MF, Skinner MA, Kündig TM, Heath MD, Johansen P. Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling. J Immunol. 2018:1;200(9):3151-3159 Lu M, Jin Y, Ballmer-Weber B, Goodman RE. A comparative study of human IgE binding to proteins of a genetically modified (GM) soybean and six non-GM soybeans grown in multiple locations.

Food and Chemical Toxicology 2018;112:216–223 Lu M, Jin Y, Cerny R, Ballmer-Weber B, Goodman RE. Combining 2-DE immunoblots and mass spectrometry to identify putative soybean (Glycine max) allergens. Food Chem Toxicol. 2018;116(Pt B): 207-215 Ma Q, Dieterich LC, Ikenberg K, Bachmann SB, Mangana J, Proulx ST, Amann VC, Levesque MP, Dummer R, Baluk P, McDonald DM, Detmar M. PF“ Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Sci Adv. 2018:8;4(8):eaat4758

Kolios AGA, Hafner J, Luder C, Guenova E, Kerl K, Kempf W, Nilsson J, French LE, Cozzio A. Comparison of pyoderma gangrenosum and Martorell hypertensive ischaemic leg ulcer in a Swiss cohort. Br J Dermatol. 2018;178(2):e125-e126

Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalker N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M. Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. J Eur Acad Dermatol Venereol. 2018 Nov 2. doi: 10.1111/ jdv.15324. [Epub ahead of print]

Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R. Increased tumour cell PD-L1-expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. J Eur Acad Dermatol Venereol. 2018 Oct 25. doi: 10.1111/jdv.15302. [Epub ahead of print]

Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, Navarini A, Abe R, Yawalkar N, Chung WH, French LE, Contassot E. Culprit drugs induce specific IL-36 overexpression in Acute Generalized Exanthematous Pustulosis. J Invest Dermatol. 2018 Nov 2. pii: S0022-202X(18)32779-9. doi: 10.1016/j.jid.2018.10.023. [Epub ahead of print]

61

Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, Kiefer B, Ospelt C, Nobbe S, Thome M, Contassot E, French LE. CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/ IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J Invest Dermatol. 2018;138(9):2010-2023 Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2018:16;106:12-23 Navarini AA, French LE. Autoinflammation behind the curtain.

Br J Dermatol 2018;3:581-582 Petridis C, Navarini AA, Dand N, Saklatvala J, Baudry D, Duckworth M, Allen MH, Curtis CJ, Lee SH, Burden AD, Layton A, Bataille V, Pink AE; Acne Genetic Study Group, Carlavan I, Voegel JJ, Spector TD, Trembath RC, McGrath JA, Smith CH, Barker JN, Simpson MA. Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne.

Nat Commun. 2018;9(1):5075 Piaggesi A, Låuchli S, Bassetto F, Biedermann T, Marques A, Najafi B, Palla I, Scarpa C, Seimetz D, Triulzi I, Turchetti G, Vaggelas A. Advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies. J Wound Care. 2018:1;27(Sup6a):S1-S137 Pich C, Meylan P, Mastelic-Gavillet B, Nguyen TN, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L. Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth. Cancer Res. 2018:15;78(22): 6447-6461 Pink A, Anzengruber F, Navarini AA. Acne and hidradenitis suppurativa. Br J Dermatol. 2018;178(3):619-631 Rabe E, Partsch H, Hafner J, Lattimer C, Mosti G, Neumann M, Urbanek T, Huebner M, Gaillard S, Carpentier P. Indications for medical compression stockings in venous and lymphatic disorders: An evidence-based consensus statement. Phlebology.

2018;33(3):163-184 Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. 2018:9;174(4):843-855.e19 Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018:9;174(4):1031-1032 Roenneberg S, Hegyi I, Kempf W, Kerl K, Guenova E. Dome-shaped papules on the left flank. Acta Derm Venereol. 2018:98;165-166 Sand J, Haertel E, Biedermann T, Contassot E, Reichmann E, French LE, Werner S, Beer HD. Expression of inflammasome proteins and inflammasome activation occurs in human, but not in murine keratinocytes. Cell Death Dis 2018;18;9(2):24

62

Saulite I, Pekar-Lukacs A, Kerl K, Cozzio A, Hoetzenecker W, Guenova E. Pseudolymphomatous Reaction to Red Tattoo Pigment.

Case Rep Dermatol. 2018:10;162-168 Saunte DML, Piraccini BM, Sergeev AY, Prohić A, Sigurgeirsson B, Rodríguez-Cerdeira C, Szepietowski JC, Faergemann J, Arabatzis M, Pereiro M, Skerlev M, Lecerf P, Schmid-Grendelmeier P, Nenoff P, Nowicki RJ, Emtestam L, Hay RJ. A survey among dermatologists: diagnostics of superficial fungal infections - what is used and what is needed to initiate therapy and assess efficacy? J Eur Acad Dermatol Venereol. 2018 Nov 23. doi: 10.1111/jdv.15361. [Epub ahead of print] Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, PhamLedard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2018 Sep 29. doi: 10.1111/bjd.17258. [Epub ahead of print] Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, Di Bona D, Pfaar O, Ahlbeck L, Akdis M, Weinfeld D, Contreras-Verduzco FA, Pedroza-Melendez A, Skaarup SH, Lee SM, Cardell LO, Schmid JM, Westin U, Dollner R, Kündig TM. Intralymphatic Immunotherapy: Update and Unmet Needs. Int Arch Allergy Immunol. 2019;178(2):141-149, Siegenthaler B, Defila C, Muzumdar S, Beer HD, Meyer M, Tanner S, Bloch W, Blank V, Schäfer M, Werner S. Nrf3 promotes UV-induced keratinocyte apoptosis through suppression of cell adhesion.

Cell Death Differ. 2018;25(10):1749-1765 Simon D, Nobbe S, Nägeli M, Barysch M, Kunz M, Borelli S, Hasan-Ali O, Wildi E, Gasser UE. Short- and long-term effects of two emollients on itching and skin restoration in xerotic eczema. Dermatol Ther.

2018;31(6):e12692.

Singer F, Irmisch A, Toussaint NC, Grob L, Singer J, Thurnherr T, Beerenwinkel N, Levesque MP, Dummer R, Quagliata L, Rothschild SI, Wicki A, Beisel C, Stekhoven DJ. SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics.

BMC Med Inform Decis Mak. 2018:29;18(1):89 Spalinger MR, Manzini R, Hering L, Riggs JB, Gottier C, Lang S, Atrott K, Fettelschoss A, Olomski F, Kündig TM, Fried M, McCole DF, Rogler G, Scharl M. PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. Cell Rep. 2018:13;22(7):1835-1848 Steiner UC, Kölliker L, Weber-Chrysochoou C, Schmid-Grendelmeier P, Probst E, Wuillemin WA, Helbling A. Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema.

Orphanet J Rare Dis. 2018:5;13(1):90

Stockfleth E, Hofbauer GFL, Reinhold U, Popp G, Hengge UR, Szeimies RM, Brüning H, Anliker M, Hunger T, Dummer R, Ulrich C, Kenzelmann R, Surber C, French LE. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. Br J Dermatol.

2018 Sep 1. doi: 10.1111/bjd.17124 Stoffel E, Maier H, Riedl E, Brüggen CM, Reininger B, Schaschinger M, Bangert C, Guenova E, Stingl G, Brunner PM. Analysis of anti-TNFinduced skin lesions reveals strong Th1 activation with some distinct immunological characteristics. Br J Dermatol.2018 May;178(5): 1151-1162 Straub Piccirillo D, Schmid-Grendelmeier P, Hitzler M, Lauener R. Continuing medical education activities for improved management of allergy patients. Allergy. 2018;73(6):1351-1353 Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer.

2018:19;104:137-144 Tschandl P, Rodendahl C, Akay BN, Argenziano G. Blum A, Braun RP, Cabo H, Gourhant JY, Kreusch J, Lallas A, Lapins J, Marghoob A, Menzies S, Neuber NM, Paoli J, Rabinovitz HS, Rinner C, Scope A, Soyer HP, Sinz C, Thomas L, Zalaudek I, Kittler H. Expert-Level Diagnosis of Nonpigmented Skin Cancer by Combined Convolutional Neural Networks. JAMA Dermatol. 2018 Nov 28. doi: 10.1001/ jamadermatol.2018.4378. [Epub ahead of print] Tusup M, Kundig T, Pascolo S. Epitranscriptomics of cancer. World J Clin Oncol, 2018:10;9(3):42-55 Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Köks S, Mrowietz U, Puig L, Reynolds N, Tan ES, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csörgő Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2018 Jul 21. pii: S0091-6749(18)31039-X. doi: 10.1016/j. jaci.2018.06.038. [Epub ahead of print] Robinson C, Inci I, Naegeli M, Murer Chr, Schuurmans M, Urosevic-Maiwald M, Schüpbach R, Weder W, Benden Chr. Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation.

Pediatr Transplant. 2018;22(3):e13145

Vukovic S, Anagnostopoulos A, Zbinden R, Schönenberger L, Guillod C, French LE, Navarini A, Roider E. Painful lymphadenopathy after an insect bite-a case report. Hautarzt. 2019;70(1):47-50 Wüthrich B, Senti G, Kündig TM. Letter to the Editor: Consensusbased European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children. J Eur Acad Dermatol Venereol, 2018;32:850-878 Wolpert F, Weller M, Berghoff A, Rushing E, Füreder L, Petyt G, Leske H, Andratschke N, Regli L, Neidert M, Stupp R, Stahel R, Dummer R, Fraufenfelder T, Roth P, Reyns N, Kaufmann P, Preusser M, Le Rhun E. Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. European Journal of Cancer 2018;96:64-72 Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V. Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. Clin Proteomics. 2018:9;15:13 Zimmerli D, Cecconi V, Valenta T, Hausmann G, Cantù C, Restivo G, Hafner J, Basler K, van den Broek M. WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma. Oncogene. 2018;37(27):3753-3762 Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell. 2018:9;34(1):69-84 Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, Buense Bedrikow R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Leslie TA, Magerl M, Mathelier-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, Oude-Elberink H, Rosumeck S, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vestergaard C, Wedi B, Werner RN, Zhao Z, Maurer M; Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.

Allergy. 2018;73(7):1393-1414

Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, Klink R; GAP investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol.

2018;141(2):529-538.e13 Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer 2018;93:158 Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, Scharl M, Schoepfer AM, Rogler G, Prinz Vavricka MB, Terracciano L, Navarini A, Zlobec I, Lugli A, Greuter T. Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):347-354.

63

Reviews 2018 Augustin M, Wimmer J, Biedermann T, Blaga R, Dierks C, Djamei V, Elmer A, Elsner P, Enk A, Gass S, Henningsen M, Hofman-Wellenhof R, von Kiedrowski R, Kunz HD, Liebram C, Navarini A, Otten M, Reusch M, Schüller C, Zink A, Strömer K. Praxis der Teledermatologie.

J Dtsch Dermatol Ges. 2018;16 Suppl 5:6-57 Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition. Oncoimmunology. 2018:23;7(9):e1468955 Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018:21;16(1):207

Rottem M, Ryan D, Salimäki J, Samolinski B, Sanchez-Borges M, Schunemann HJ, Sheikh A, Sisul JC, Rajabian-Söderlund R, Sooronbaev T, Stellato C, To T, Todo-Bom AM, Tomazic PV, Toppila-Salmi S, Valero A, Valiulis A, Valovirta E, Ventura MT, Wagenmann M, Wang Y, Wallace D, Waserman S, Wickman M, Yorgancioglu A, Zhang L, Zhong N, Zidarn M, Zuberbier T; Mobile Airways Sentinel Network (MASK) Study Group. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology.

J Allergy Clin Immunol. 2018 Sep 29. pii: S0091-6749(18)31359-9. doi: 10.1016/j.jaci.2018.08.049. [Epub ahead of print] Buechner AA, Theiler M, Krayenbuehl B, Weibel L. Topical Tacalcitol for Family Occurrence of Follicular Keratosis of the Chin. JAMA Dermatol.2018;154(1):111-112

Ballmer-Weber BK, Beyer K. Food challenges. J Allergy Clin Immunol.

2018;141:69-71

Dimitriou F, Braun RP, Mangana J. Update on adjuvant melanoma therapy. Curr Opin Oncol.2018; 30(2):118-124

Barysch MJ, Mangana J, Dummer R. A new B-Raf inhibitor combo for advanced melanoma. Oncotarget. 2018:2;9(77):34457-34458

Dimitriou F, Krattinger R, Ramelyte E, Barysch MJ, Micaletto S, Dummer R, Goldinger SM. The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Curr Oncol Rep. 2018:24;20(11):87

Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067-1077.

Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, MathieuDupas E, Murray R, Onorato GL, Pépin JL, Picard R, Portejoie F, Costa E, Fonseca J, Lourenço O, Morais-Almeida M, Todo-Bom A, Cruz AA, da Silva J, Serpa FS, Illario M, Menditto E, Cecchi L, Monti R, Napoli L, Ventura MT, De Feo G, Larenas-Linnemann D, Fuentes Perez M, Huerta Villabolos YR, Rivero-Yeverino D, Rodriguez-Zagal E, Amat F, Annesi-Maesano I, Bosse I, Demoly P, Devillier P, Fontaine JF, Just J, Kuna TP, Samolinski B, Valiulis A, Emuzyte R, Kvedariene V, Ryan D, Sheikh A, Schmidt-Grendelmeier P, Klimek L, Pfaar O, Bergmann KC, Mösges R, Zuberbier T, Roller-Wirnsberger RE, Tomazic P, Fokkens WJ, Chavannes NH, Reitsma S, Anto JM, Cardona V, Dedeu T, Mullol J, Haahtela T, Salimäki J, Toppila-Salmi S, Valovirta E, Gemicioğlu B, Yorgancioglu A, Papadopoulos N, Prokopakis EP, Bosnic-Anticevich S, O›Hehir R, Ivancevich JC, Neffen H, Zernotti E, Kull I, Melen E, Wickman M, Bachert C, Hellings P, Palkonen S, Bindslev-Jensen C, Eller E, Waserman S, Sova M, De Vries G, van Eerd M, Agache I, Casale T, Dykewickz M, Naclerio RN, Okamoto Y, Wallace DV; MASK study group. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018:25;8:45 Bousquet J, Hellings PW, Agache I, Amat F, Annesi-Maesano I, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bedbrook A, Bennoor K, Bewick M, Bindslev-Jensen C, Bosnic-Anticevich S, Bosse I, Brozek J, Brussino L, Canonica GW, Cardona V, Casale T, Cepeda Sarabia AM, Chavannes NH, Cecchi L, Correia de Sousa J, Costa E, Cruz AA, Czarlewski W, De Carlo G, De Feo G, Demoly P, Devillier P, Dykewicz MS, El-Gamal Y, Eller EE, Fonseca JA, Fontaine JF, Fokkens WJ, Guzmán MA, Haahtela T, Illario M, Ivancevich JC, Just J, Kaidashev I, Khaitov M, Kalayci O, Keil T, Klimek L, Kowalski ML, Kuna P, Kvedariene V, Larenas-Linnemann D, Laune D, Le LTT, Carlsen KL, Lourenço O, Mahboub B, Mair A, Menditto E, Milenkovic B, Morais-Almeida M, Mösges R, Mullol J, Murray R, Naclerio R, Namazova-Baranova L, Novellino E, O›Hehir RE, Ohta K, Okamoto Y, Okubo K, Onorato GL, Palkonen S, Panzner P, Papadopoulos NG, Park HS, Paulino E, Pawankar R, Pfaar O, Plavec D, Popov TA, Potter P, Prokopakis EP,

64

Dummer R. The dynamics of medical care in skin cancers. Curr Opin Oncol. 2018;30(2):105-106 Dubois AEJ, Turner PJ, Hourihane J, Ballmer-Weber B, Beyer K, Chan CH, Gowland MH, O›Hagan S, Regent L, Remington B, Schnadt S, Stroheker T, Crevel RWR. How does dose impact on the severity of food-induced allergic reactions, and can this improve risk assessment for allergenic foods?: Report from an ILSI Europe Food Allergy Task Force Expert Group and Workshop. Allergy 2018;73(7):1383-1392 Gerth van Wijk R, Eguiluz-Gracia I, Gayraud J, Gutermuth J, Hamelmann E, Heffler E, Popov TA, Schmid-Grendelmeier P, Tomazic PV, Tsilochristou O, Muelleneisen N. The roadmap for allergology in Europe: The subspecialty of allergology as «stop-over» on the way to a full specialty. An EAACI position statement. Allergy.

2018;73(3):540-548 Gilles S, Akdis C, Lauener R, Schmid-Grendelmeier P, Bieber T, Schäppi G, Traidl-Hoffmann C. The role of environmental factors in allergy: A critical reappraisal. Exp Dermatol. 2018;27(11):1193-1200 Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol. 2018;19(12):e720-e725 Gutzmer R, Harrington KJ, Hoeller C, Lebbé C, Malvehy J, Öhrling K, Downey G, Dummer R. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Eur J Dermatol. 2018:1;28(6):736-749 Henning P, Garstkiewicz M, Grossi S, Di Filippo M, French LE, Beer HD. The Crosstalk between Nrf2 and Inflammasomes. Int J Mol Sci, 2018;13;19(2) Hogan S, Levesque MP, Cheng PF. Melanoma Immunotherapy: Next-Generation Biomarkers. Frontiers in Oncology 2018;8:178

Iselin C, Guenova E. Periphere T-Zell Lymphome. Info@onkologie.

2018;5:30-33 Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol.

2018;30(2):125-133 Koelblinger P, Dummer R, Laimer M, Hecht S, Bauer JW, Gaggl A, Kugler A. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient. J Eur Acad Dermatol Venereol. 2018;32(1):e7-e8.

Kolios AGA, Biedermann L, Weber A, Navarini AA, Meier J, Cozzio A, French LE. Paradoxical ulcerative colitis during Adalimumab treatment of psoriasis resolved by switch to Ustekinumab.

Br J Dermatol. 2018;178(2):551-555 Kolios AGA, Hafner J, Luder C, Guenova E, Kerl K, Kempf W, Nilsson J, French LE, Cozzio A. Comparison of pyoderma gangrenosum and hypertensive ischemic leg ulcer Martorell in a Swiss cohort.

Br J Dermatol.2018;178(2):e125-e126 Luder CM, Nordmann TM, Ramelyte E, Mühleisen B, Kerl K, Guenova E, Dummer R. Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations.

J Eur Acad Dermatol Venereol. 2018;32(6):926-934 Meyer Sauteur PM, Orban P, Theiler M. Recurrent superficial lymphangitis after insect bites. Arch Dis Child. 2018;103(3):296 Navarini AA, French LE. Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice. J Invest Dermatol 2018;4:726-728 Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms Underlying the Clinical Effects of Aprimilast for Psoriasis.

J Drugs Dermatol, 2018;8:835-840 Rabe E, Partsch H, Hafner J, Lattimer C, Mosti G, Neumann M, Urbanek T, Huebner M, Gaillard S, Carpentier P. Indications for medical compression stockings in venous and lymphatic disorders: An evidence-based consensus statement. Phlebology.2018 Apr;33(3):163-184 Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and Angioedema: an Update on Classification and Pathogenesis. Clin Rev Allergy Immunol.

2018;54(1):88-101 Roenneberg S, Hegyi I, Kempf W, Kerl K, Guenova E. Dome-shaped Papules on the Left Flank: A Quiz. Acta Derm Venereol. 2018;98(1): 165-166 Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018;8(5):568-581 Tétu P, Mangana J, Dummer R, Dutriaux C, Beneton N, Dalle S, Meyer N, Oriano B, Michielin O, Lebbe C. Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Eur J Cancer. 2018;93:147-149

Theiler M, Schwieger-Briel A, Cont M, Relly C, Meyer Sauteur PM. Bilateral palatine ulcers in a neonate: Bednar›s aphthae.

Arch Dis Child.2018;103(11):1020 Tsilochristou O, Maggina P, Zolkipli Z, Sanchez Garcia S, Uysal P, Alvaro Lozano M, Atanaskovic-Markovic M, Baghdasaryan A, Beyer K, DuToit G, Gerth van Wijk R, Høst A, O›Hourihane J, Ingemann L, Kivistö JE, Lopes Dos Santos JM, Melén E, Muraro A, Nieto A, Pajno G, Rose K, Réthy LA, Sackesen C, Schmid-Grendelmeier P, Valovirta E, Wickman M, Eigenmann PA, Wahn U, van der Poel LA. Current state and future of pediatric allergology in Europe: A road map. Pediatr Allergy Immunol. 2018;29(1):9-17 Wollenberg A, Schmid-Grendelmeier P, Christen-Zäch S, Ring J. Reply to a correspondence addressing the European guideline for treatment of atopic eczema, functional textiles and the CLOTHES trial. J Eur Acad Dermatol Venereol. 2018 Dec 5. doi: 10.1111/jdv.15384.

[Epub ahead of print] Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, Czarnecka- Operacz M, Schäfer T, Schmid-Grendelmeier P, Simon D, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T, Ring J; European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878 Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, CzarneckaOperacz M, Schäfer T, Schmid-Grendelmeier P, Simon D, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T, Ring J; European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682 Wüthrich B, Schmid-Grendelmeier P. The Atopic March. Allergy.

2018;73(8):1753 Yélamos O, Braun RP, Liopyris K, Wolner ZJ, Kerl K, Gerami P, Marghoob A. Dermoscopy / deramtoscopy and dermatopathology correlates of cutaneous neoplasms. J Am Acad Dermatol.

2019;80(2):341-363 Yélamos O, Braun RP, Liopyris K, Wolner ZH, Kerl K, Gerami P, Marghoob A. Usefulness of Dermoscopy / dermatoscopy to improve the clinical and histo pathologic diagnosis of skin cancers.

J Am Acad Dermatol. 2019 Feb;80(2):365-377. doi: 10.1016/j. jaad.2018.07.072. Epub 2018 Oct 13. Review.

65

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, Buense Bedrikow R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Leslie TA, Magerl M, Mathelier-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, OudeElberink H, Rosumeck S, Saini SS, Sánchez-Borges M, SchmidGrendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vestergaard C, Wedi B, Werner RN, Zhao Z, Maurer M; Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/ GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414

66

University Hospital Zurich Department of Dermatology Gloriastrasse 31 8091 Zurich c.frey-blanc@usz.ch www.dermatologie.usz.ch

Follow UHZ on